MEDICARE COVERAGE OF LABORATORY TESTING

Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply:

1. Only tests that are medically necessary for the diagnosis or treatment of the patient should be ordered. Medicare does not pay for screening tests except for certain specifically approved procedures and may not pay for non-FDA approved tests or those tests considered experimental.
2. If there is reason to believe that Medicare will not pay for a test, the patient should be informed. The patient should then sign an Advance Beneficiary Notice (ABN) to indicate that he or she is responsible for the cost of the test if Medicare denies payment.
3. The ordering physician must provide an ICD-10 diagnosis code or narrative description, if required by the fiscal intermediary or carrier.
4. Organ- or disease-related panels should be billed only when all components of the panel are medically necessary.
5. Both ARUP- and client-customized panels should be billed to Medicare only when every component of the customized panel is medically necessary.
6. Medicare National Limitation Amounts for CPT codes are available through the Centers for Medicare & Medicaid Services (CMS) or its intermediaries. Medicaid reimbursement will be equal to or less than the amount of Medicare reimbursement.

The CPT Code(s) for test(s) profiled in this bulletin are for informational purposes only. The codes reflect our interpretation of CPT coding requirements, based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist you in billing. ARUP strongly recommends that clients reconfirm CPT code information with their local intermediary or carrier. CPT coding is the sole responsibility of the billing party.

The regulations described above are only guidelines. Additional procedures may be required by your fiscal intermediary or carrier.

<table>
<thead>
<tr>
<th>Hotline Page #</th>
<th>Test Number</th>
<th>Name Change</th>
<th>Methodology</th>
<th>Performed/Reported Schedule</th>
<th>Specimen Requirements</th>
<th>Reference Interval</th>
<th>Interpretive Data</th>
<th>Note</th>
<th>CPT Code</th>
<th>Component Change</th>
<th>Other Interface Change</th>
<th>New Test</th>
<th>Inactive</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>0060245</td>
<td>Acanthamoeba and Naegleria Culture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>3000878</td>
<td>Acanthamoeba and Naegleria Culture and Stain, CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2002584</td>
<td>Acanthamoeba and Naegleria Culture and Stains, CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>2014521</td>
<td>Acetaminophen Quantitative, Urine</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0065066</td>
<td>Adenovirus 40-41 Antigens by EIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>2012710</td>
<td>Aggressive B-Cell Lymphoma FISH Reflex, Tissue</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2014168</td>
<td>Alagille Syndrome (JAG1) Sequencing and Microarray</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotline Page #</td>
<td>Test Number</td>
<td>Summary of Changes by Test Name</td>
<td>Name Change</td>
<td>Methodology</td>
<td>Performed/Reported Schedule</td>
<td>Specimen Requirements</td>
<td>Reference Interval</td>
<td>Interpretive Data</td>
<td>Note</td>
<td>CPT Code</td>
<td>Component Change</td>
<td>Other Interface Change</td>
<td>New Test</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>-----------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>9</td>
<td>2011431</td>
<td>ALK (D5F3) by Immunohistochemistry with Reflex to ALK Gene Rearrangements by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2006102</td>
<td>ALK Gene Rearrangements by FISH, Lung</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>3001302</td>
<td>ALK Gene Rearrangements by FISH, Lung</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0055422</td>
<td>Allergen, Drugs, Ampicillin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091204</td>
<td>Allopurinol and Metabolite, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>0080500</td>
<td>Alpha-1-Antitrypsin Phenotype (Includes Alpha-1-Antitrypsin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>3001257</td>
<td>Alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by IFA with Reflex to Titer, CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>3001260</td>
<td>Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by IFA with Reflex to Titer, Serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>0090161</td>
<td>Amiodarone and Metabolite</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>0060250</td>
<td>Amoeba Calcofluor Stain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091236</td>
<td>Amoxapine and Metabolite Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>0099007</td>
<td>Antimony, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>2007945</td>
<td>Aripiprazole and Metabolite, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>3001283</td>
<td>Autoimmune CNS Demyelinating Disease Reflexive Panel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>2008665</td>
<td>Babesia Species by PCR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2010107</td>
<td>BCL6 (3q27) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>3001311</td>
<td>BCL6 (3q27) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>3000967</td>
<td>Beryllium Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091278</td>
<td>Beryllium, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>0099478</td>
<td>Bismuth, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>2011436</td>
<td>Bromide, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2012002</td>
<td>Bruton Tyrosine Kinase (BTK) Protein Expression by Flow Cytometry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>2010357</td>
<td>Bupropion, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>0050301</td>
<td>C1q Binding Assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>3001129</td>
<td>Capillary Malformation-Arteriovenous Malformation 2 (EPHB4) Sequencing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>0091352</td>
<td>Carbidopa and Levodopa Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotline Page #</td>
<td>Test Number</td>
<td>Name Change Methodology</td>
<td>Performed/Reported Schedule Specimen Requirements Reference Interval Interpretive Data Note CPT Code Component Change Other Interface Change New Test Inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>-------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>2011450</td>
<td>Carisoprodol and Meprobamate, Serum or Plasma, Quantitative</td>
<td>x x x x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>2012219</td>
<td>Carisoprodol and Meprobamate, Urine, Quantitative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091223</td>
<td>Clonidine, Urine</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>3001132</td>
<td>Capillary Malformation-Arteriovenous Malformation (EPHB4 and RASA1) Sequencing, and (RASA1) Deletion/Duplication</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2006220</td>
<td>Congenital Amegakaryocytic Thrombocytopenia (CAMT) Sequencing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>0020414</td>
<td>Creatine Kinase Isoenzymes</td>
<td>x x x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>0090060</td>
<td>Cyanide</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091303</td>
<td>Cyclobenzaprine Quantitative, Serum or Plasma</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2003845</td>
<td>Cytokeratin 19 (CK 19) by Immunohistochemistry</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2007223</td>
<td>Ddit3 (CHOP) (12q13) Gene Rearrangement by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>3001304</td>
<td>Ddit3 (CHOP) (12q13) Gene Rearrangement by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>2011487</td>
<td>Desipramine, Serum or Plasma by Tandem Mass Spectrometry</td>
<td>x x x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2006236</td>
<td>Diamond-Blackfan Anemia (RPL11) Sequencing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2006234</td>
<td>Diamond-Blackfan Anemia (RPL5) Sequencing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2006238</td>
<td>Diamond-Blackfan Anemia (RPS19) Sequencing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>0090080</td>
<td>Digoxin</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>0090499</td>
<td>Drug Screen (Nonforensic), Serum</td>
<td>x x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>0090500</td>
<td>Drug Screen (Nonforensic), Urine, Qualitative</td>
<td>x x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2006244</td>
<td>Dyskeratosis Congenita, Autosomal (TERC) Sequencing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2006228</td>
<td>Dyskeratosis Congenita, X-linked (DKC1) Sequencing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2008605</td>
<td>EGFR Gene Amplification by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>3001310</td>
<td>EGFR Gene Amplification by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>2002440</td>
<td>EGFR Mutation Detection by Pyrosequencing</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>2007862</td>
<td>Ehrlichia and Anaplasma Species by PCR</td>
<td>x x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>0051002</td>
<td>Ehrlichia chaffeensis Antibodies, IgG &amp; IgM by IFA</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>0051004</td>
<td>Ehrlichia chaffeensis Antibody, IgG by IFA</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>0051003</td>
<td>Ehrlichia chaffeensis Antibody, IgM by IFA</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>2007909</td>
<td>Ethyl Glucuronide and Ethyl Sulfate, Urine, Quantitative</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotline Page #</td>
<td>Test Number</td>
<td>Summary of Changes by Test Name</td>
<td>Name Change</td>
<td>Methodology</td>
<td>Performed/Reported Schedule</td>
<td>Specimen Requirements</td>
<td>Reference Interval</td>
<td>Interpretive Data</td>
<td>Note</td>
<td>CPT Code</td>
<td>Component Change</td>
<td>Other Interface Change</td>
<td>New Test</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>------------------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>------</td>
<td>----------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>58</td>
<td>2007225</td>
<td>EWSR1 (22q12) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>3001305</td>
<td>EWSR1 (22q12) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>2013694</td>
<td>Explify Respiratory Pathogens by Next Generation Sequencing (Pricing Change Only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>2011776</td>
<td>Fentanyl and Metabolite, Serum or Plasma, Quantitative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2007883</td>
<td>Filagrin (FLG) 2 Mutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>0090003</td>
<td>Flecainide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>3001161</td>
<td>FLT3 ITD and TKD Mutation Detection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091517</td>
<td>Formic Acid, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2001497</td>
<td>FOX01 (FKHR) (13q14) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>3001297</td>
<td>FOX01 (FKHR) (13q14) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>0090057</td>
<td>Gabapentin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>2012227</td>
<td>Gabapentin, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>3001267</td>
<td>Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody, IgG by IFA with Reflex to Titer, CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>3001270</td>
<td>Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody, IgG by IFA with Reflex to Titer, Serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>3001284</td>
<td>Herpesvirus 6 Antibody, IgM by IFA, Serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2011420</td>
<td>Herpesvirus 6 Antibody, IgM Screen with Reflex to Titer by IFA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>3001393</td>
<td>HLA-B*58:01 Genotyping, Allopurinol Hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>2010292</td>
<td>Hypoglycemia Panel, Sulfonylureas Qualitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>2014183</td>
<td>Ibuprofen Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2001536</td>
<td>IGH-BCL2 Fusion, t(14;18) by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>3001298</td>
<td>IGH-BCL2 Fusion, t(14;18) by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>3001306</td>
<td>IGH-CCND1 Fusion, t(11;14) by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2007226</td>
<td>IGH-CCND1 Fusion, t(11;14) by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2001538</td>
<td>IGH-MYC Fusion t(8;14) by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>3001299</td>
<td>IGH-MYC Fusion t(8;14) by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>0050667</td>
<td>Immune Complex Panel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotline Page #</td>
<td>Test Number</td>
<td>Name</td>
<td>Methodology</td>
<td>Performed/Reported Schedule</td>
<td>Specimen Requirements</td>
<td>Reference Interval</td>
<td>Interpretive Data</td>
<td>Note</td>
<td>CPT Code</td>
<td>Component Change</td>
<td>Other Interface Change</td>
<td>New Test</td>
<td>Inactive</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>------</td>
<td>----------</td>
<td>------------------</td>
<td>----------------------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>34</td>
<td>2012084</td>
<td>JAK2 Gene, V617F Mutation, Qualitative with Reflex to CALR (Calreticulin) Exon 9 Mutation Analysis by PCR with Reflex to MPL Mutation Detection</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>0040105</td>
<td>Kleihauer-Betke Stain for Fetal Hemoglobin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>0050021</td>
<td>LDL Subclasses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2014683</td>
<td>LeukoStrat CDx FLT3 Mutation Detection by PCR</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>2008894</td>
<td>Lung Cancer Panel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>2008895</td>
<td>Lung Cancer Panel with KRAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>0099272</td>
<td>Manganese, Whole Blood</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>2014704</td>
<td>Maternal T Cell Engraftment in SCID, Maternal Specimen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2003016</td>
<td>MDM2 Gene Amplification by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>3001301</td>
<td>MDM2 Gene Amplification by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>3001158</td>
<td>Melatonin Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>2011521</td>
<td>Meprobamate, Serum or Plasma, Quantitative</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2013082</td>
<td>MET Gene Amplification by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>3001313</td>
<td>MET Gene Amplification by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091090</td>
<td>Methaqualone Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>2011539</td>
<td>Mexiletine, Serum or Plasma</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>0051740</td>
<td>Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>2005545</td>
<td>MPL Mutation Detection by Capillary Electrophoresis</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2002345</td>
<td>MYC (8q24) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>3001300</td>
<td>MYC (8q24) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>3001307</td>
<td>MYCN (N-MYC) Gene Amplification by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2007227</td>
<td>MYCN (N-MYC) Gene Amplification by FISH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>2010359</td>
<td>Mycophenolic Acid and Metabolites</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>3001277</td>
<td>Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0099685</td>
<td>Neisseria gonorrhoea Antibodies, Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>3001291</td>
<td>Neisseria gonorrhoeae Antibody by CF, Serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>0099452</td>
<td>Nickel, Serum</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>0099289</td>
<td>Organic Acids, Plasma</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>2002277</td>
<td>Ova and Parasite Exam, Body Fluid or Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Hotline Page #</td>
<td>Test Number</td>
<td>Summary of Changes by Test Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>---------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Name Change</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methodology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Performed/Reported Schedule</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Specimen Requirements</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reference Interval</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interpretive Data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Note</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CPT Code</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Component Change</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other Interface Change</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>New Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>0098834</td>
<td>Oxcarbazepine or Eslicarbazepine Metabolite (MHD)</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2008604</td>
<td>1p/19q Deletion by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>3001309</td>
<td>1p/19q Deletion by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>2007949</td>
<td>Paliperidone, Serum or Plasma</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>2013284</td>
<td>PD-L1 22C3 IHC with Tumor Proportion Score (TPS) Interpretation, pembrolizumab (KEYTRUDA)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>2011549</td>
<td>Pentobarbital, Serum or Plasma</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2003237</td>
<td>PhenoSense Entry</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2003235</td>
<td>PhenoSense Integrase Inhibitor</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051309</td>
<td>Platelet Antigen 1 Genotyping (HPA-1)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>3001170</td>
<td>Platelet Antigen 1 Genotyping (HPA-1)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051314</td>
<td>Platelet Antigen 15 Genotyping (HPA-15)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051310</td>
<td>Platelet Antigen 2 Genotyping (HPA-2)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051311</td>
<td>Platelet Antigen 3 Genotyping (HPA-3)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051490</td>
<td>Platelet Antigen 4 Genotyping (HPA-4)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051312</td>
<td>Platelet Antigen 5 Genotyping (HPA-5)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051313</td>
<td>Platelet Antigen 6 Genotyping (HPA-6)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>3000193</td>
<td>Platelet Antigen Genotyping Panel</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0051308</td>
<td>Platelet Antigen Genotyping Panel</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>2011609</td>
<td>Pregabalin, Serum or Plasma</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>2012229</td>
<td>Pregabalin, Urine</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2007533</td>
<td>Progressive Myoclonic Epilepsy (PME) Panel, Sequence Analysis and Exon-Level Deletion/Duplication</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>3000134</td>
<td>Prostate Health Index</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2004091</td>
<td>Protein Gene Product (PGP) 9.5 by Immunohistochemistry</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>3001255</td>
<td>14-3-3 Protein Tau, Total, CSF</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2008095</td>
<td>14-3-3 Protein Tau/Theta, CSF</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>2003118</td>
<td>Quetiapine, Serum or Plasma</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2012654</td>
<td>RET Gene Rearrangements by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>3001312</td>
<td>RET Gene Rearrangements by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>2007951</td>
<td>Risperidone and Metabolite, Serum or Plasma</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2008418</td>
<td>ROS1 by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>3001308</td>
<td>ROS1 by FISH</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotline Page #</td>
<td>Test Number</td>
<td>Summary of Changes by Test Name</td>
<td>Name Change</td>
<td>Methodology</td>
<td>Performed/Reported Schedule</td>
<td>Specimen Requirements</td>
<td>Reference Interval</td>
<td>Interpretive Data</td>
<td>Note</td>
<td>CPT Code</td>
<td>Component Change</td>
<td>Other Interface Change</td>
<td>New Test</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>----------------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>50</td>
<td>2008414</td>
<td>ROS1 with Interpretation by Immunohistochemistry with Reflex to FISH if Equivocal or Positive</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0065067</td>
<td>Rotavirus and Adenovirus 40-41 Antigens</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>0098745</td>
<td>Sertraline</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2007222</td>
<td>SS18 (SYT) (18q11) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>3001303</td>
<td>SS18 (SYT) (18q11) Gene Rearrangement by FISH</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>2002270</td>
<td>ST2, Soluble</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091574</td>
<td>Strychnine, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>0020044</td>
<td>Sulfonamides (Sulfas)</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>2003128</td>
<td>Tapentadol and Metabolite, Urine, Quantitative</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091386</td>
<td>Temazepam and Metabolite Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>0099610</td>
<td>Thallium, Whole Blood</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>0090064</td>
<td>Thiocyanate, 24-Hour Urine</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>0090063</td>
<td>Thiocyanate, Random Urine</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>2011575</td>
<td>Thiocyanate, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>0056200</td>
<td>Thrombotic Risk, DNA Panel</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>3001184</td>
<td>Tiagabine Quantitative, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091541</td>
<td>Tiagabine, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>2008670</td>
<td>Tick-Borne Disease Panel by PCR, Blood</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091555</td>
<td>Tin, Total, Whole Blood</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>2007515</td>
<td>Tricyclic Antidepressants, Quantitative, Urine</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091399</td>
<td>Trihexyphenidyl Quantitative, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0091396</td>
<td>Trimethoprim, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>2004747</td>
<td>Trofile DNA Co-Receptor Tropism Assay</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>3001149</td>
<td>Uroplakin II by Immunohistochemistry</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>2005415</td>
<td>Urticaria-Inducing Activity with Thyroid Antibodies and Stimulating Hormone</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>2007957</td>
<td>Venlafaxine and Metabolite, Serum or Plasma</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>0020056</td>
<td>Viscosity, Serum</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>0020054</td>
<td>Viscosity, Whole Blood</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>0080111</td>
<td>Vitamin B6 (Pyridoxal 5-Phosphate)</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>3001387</td>
<td>Voltage-Gated Potassium Channel (VGKC) Antibody, CSF</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>2004890</td>
<td>Voltage-Gated Potassium Channel (VGKC) Antibody, Serum</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotline Page #</td>
<td>Test Number</td>
<td>Summary of Changes by Test Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>---------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>2009373</td>
<td>Zinc Quantitative, Whole Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Number</th>
<th>Methodology</th>
<th>Performed/Rpt Schedule</th>
<th>Specimen Requirements</th>
<th>Reference Interval</th>
<th>Interpretive Data</th>
<th>Component Change</th>
<th>New Test</th>
<th>Inactive</th>
</tr>
</thead>
<tbody>
<tr>
<td>3000878</td>
<td>Qualitative Culture/Microscopy/Giemsa Stain</td>
<td>Sun-Sat</td>
<td>2-10 days</td>
<td>Collect: CSF. Transfer 1 mL CSF to a sterile ARUP Standard Transport Tube (ARUP supply # 43115) available online through eSupply using ARUP Connect™ or contact Client Services at (800) 522-2787. (Min: 0.5 mL)</td>
<td>Storage/Transport Temperature: Room temperature. Unacceptable Conditions: Specimens in media or preservatives. Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: Unacceptable; Frozen: Unacceptable</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**New Test**  
3000878  

**Acanthamoeba and Naegleria Culture**  
**ACANT CSF**

**Note:** For CSF refer to *Acanthamoeba and Naegleria Culture and Stain, CSF (ARUP test code 3000878)*. For *Entamoeba histolytica* detection refer to *Entamoeba histolytica Antigen, EIA (ARUP test code 0058001)*.

**Methodology:** Qualitative Culture/Microscopy/Giemsa Stain  
**Performed:** Sun-Sat  
**Reported:** 2-10 days  
**Specimen Required:** Collect: CSF. Transfer 1 mL CSF to a sterile ARUP Standard Transport Tube (ARUP supply # 43115) available online through eSupply using ARUP Connect™ or contact Client Services at (800) 522-2787. (Min: 0.5 mL)  
**Storage/Transport Temperature:** Room temperature. Unacceptable Conditions: Specimens in media or preservatives. Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: Unacceptable; Frozen: Unacceptable  

**Reference Interval:** Negative  

**Interpretive Data:** The stain will detect free-living amoeba such as *Naegleria fowleri*, and *Balamuthia mandrillaris*.  
The culture will detect free-living amoeba such as *Acanthamoeba* species and *Naegleria fowleri*, but will NOT detect *Balamuthia mandrillaris*.  

**Note:** For all other specimen types refer to *Acanthamoeba and Naegleria Culture (ARUP test code 0060245)* and *Amoeba Calcofluor Stain (ARUP test code 0060250)*. For *Entamoeba histolytica* detection refer to *Entamoeba histolytica Antigen, EIA (ARUP test code 0058001)*.

**CPT Code(s):** 87081; 87207  

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
Acetaminophen Quantitative, Urine

Methodology: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Specimen Required: Collect: Random urine.
Specimen Preparation: Transfer 1 mL urine to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Storage/Transport Temperature: Refrigerated. Also acceptable: Room temperature or frozen.
Stability (collection to initiation of testing): Ambient: 1 month; Refrigerated: 1 month; Frozen: 1 month

Aggressive B-Cell Lymphoma FISH Reflex, Tissue

Note: If MYC (8q24) Gene Rearrangement by FISH is positive then IGH-BCL2 Fusion, t(14;18) by FISH will be added. If result is negative then BCL6 (3q27) Gene Rearrangement by FISH will be added. Additional charges apply.

HOTLINE NOTE: There is a reflexive pattern change associated with this test.
Remove reflex to 2001536, IGH-BCL2 t(14;18) by FISH
Remove reflex to 2010107, BCL6 (3q27) Gene Rearrangement by FISH
Add reflex to 3001298, IGH-BCL2 t(14;18), FISH
Add reflex to 3001311, BCL6 (3q27) Gene Rearrangement, FISH

ALK (D5F3) by Immunohistochemistry with Reflex to ALK Gene Rearrangements by FISH

HOTLINE NOTE: There is a reflexive pattern change associated with this test.
Remove reflex to 2006102, ALK by FISH, Lung
Add reflex to 3001302, ALK FISH, Lung
Additional Technical Information

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday-Friday

**Reported:** 3-7 days

**Specimen Required:**
- **Collect:** Tumor tissue.
- **Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed tumor tissue. Protect paraffin block and/or slides from excessive heat. Transport tissue block or 4 unstained, consecutively cut, 4-micron thick sections, mounted on positively charged glass slides in a tissue transport kit (ARUP supply #47808 recommended but not required) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 4 slides)
- **Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated.
- **Remarks:** Include surgical pathology report with reason for referral. The laboratory will not reject specimens that arrive without a pathology report but will hold the specimen until this information is received.
- **Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5).
- **No tumor in tissue. Decalcified specimens.**

**Reference Interval:** By report

**Interpretive Data:**
Refer to report.
See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

**0080500**

**Alpha-1-Antitrypsin Phenotype (Includes Alpha-1-Antitrypsin)**

**Specimen Required:**
- **Collect:** Serum Separator Tube (SST) or Plain Red.
- **Specimen Preparation:** Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
- **Storage/Transport Temperature:** Refrigerated.
- **Unacceptable Conditions:** Grossly hemolyzed specimens.

**Stability (collection to initiation of testing):**
- After separation from cells: Ambient: 1 week; Refrigerated: 3 months; Frozen: 3 months (avoid repeated freeze/thaw cycles)
| New Test  | 3001257 | Alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by IFA with Reflex to Titer, CSF | AMPA CSF |

**Methodology:** Semi-Quantitative Indirect Fluorescent Antibody

**Performed:** Wed

**Reported:** 1-8 days

**Specimen Required:**
- **Collect:** CSF.
- **Specimen Preparation:** Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)
- **Storage/Transport Temperature:** Refrigerated.
- **Unacceptable Conditions:** Hemolyzed, contaminated, or severely lipemic specimens.
- **Stability (collection to initiation of testing):** Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

**Reference Interval:** Less than 1:1

**Interpretive Data:** Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes AMPA transfected cell lines for detection and semi-quantification of AMPA IgG antibody.

See Compliance Statement D: www.arulab.com/CS

**Note:** If Alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by IFA with Reflex to Titer, CSF IgG is positive, then an Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody Titer, IgG, CSF is reported. Additional charges apply.

**CPT Code(s):** 86255; if reflexed, add 86256

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
New Test 3001260  Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by IFA with Reflex to Titer, Serum

Methodology: Semi-quantitative Indirect Fluorescent Antibody
Performed: Wed
Reported: 1-8 days

Specimen Required: Collect: Serum Separator Tube (SST) or Plain Red.
Specimen Preparation: Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Hemolyzed, contaminated, or severely lipemic specimens.
Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval: Less than 1:10

Interpretive Data: Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes AMPA transfected cell lines for the detection and semi-quantification of AMPA IgG antibody.

See Compliance Statement D: www.aruplab.com/CS

Note: If Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody, IgG by IFA with Reflex to Titer, Serum is positive, then an Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antibody Titer, IgG, Serum is reported. Additional charges apply.

CPT Code(s): 86255; if reflexed, add 86256

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.
Antimony, Blood

Performed: Sun-Sat
Reported: 1-3 days

Specimen Required:
- Patient Prep: Diet, medication, and nutritional supplements may introduce interfering substances. Patient should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician).
- Collect: Royal Blue (K$_2$EDTA or Na$_2$EDTA).
- Specimen Preparation: Transport 7 mL whole blood in the original collection tube. (Min: 0.5 mL)
- Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated.
- Unacceptable Conditions: Specimens collected in tubes other than Royal Blue (EDTA). Specimens transported in containers other than a Royal Blue (EDTA) tube or Trace Element-Free Transport Tube. Heparin anticoagulant. Clotted specimens.

Stability (collection to initiation of testing):
- Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Reference Interval: Effective February 19, 2019
- Less than or equal to 6.0 µg/L

Interpretive Data: Elevated results may be due to skin or collection-related contamination, including the use of a noncertified metal-free collection/transport tube. If contamination concerns exist due to elevated levels of blood antimony, confirmation with a second specimen collected in a certified metal-free tube is recommended.

Blood antimony levels predominantly reflect recent exposure and are most useful in the diagnosis of acute poisoning. Blood concentrations in unexposed individuals rarely exceed 10 µg/L. The form of antimony greatly influences distribution and elimination. Trivalent antimony readily enters red blood cells, has an extended half-life on the order of weeks to months, and is eliminated predominantly through the bile. Pentavalent antimony resides in the plasma, has a relatively short half-life on the order of hours to days, and is eliminated predominantly through the kidneys. Reported symptoms after toxic antimony exposure vary based upon route of exposure, duration and antimony source and may include abdominal pain, dyspnea, nausea, vomiting, dermatitis and eye irritation. Clinical presentation is similar to that of inorganic arsenic exposure.

See Compliance Statement B: www.aruplab.com/CS

HOTLINE NOTE: Remove information found in the Note field. There is also a numeric map change associated with this test. Change the numeric map for component 0099007, Antimony Blood from XXX to XX.X.

Aripiprazole and Metabolite, Serum or Plasma

Performed: Wed, Sat
Reported: 1-5 days

Specimen Required:
- Patient Prep: Pre-dose (trough) draw - At steady state concentration.
- Collect: Plain Red. Also acceptable: Lavender (EDTA) or Pink (K$_2$EDTA).
- Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- Storage/Transport Temperature: Refrigerated.
- Unacceptable Conditions: Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).

Stability (collection to initiation of testing):
- Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 weeks

HOTLINE NOTE: Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test. Remove component 2011432, Aripiprazole Dose
Remove component 2011433, Aripiprazole Dose Frequency
Remove component 2011434, Aripiprazole Route
Remove component 2011435, Aripiprazole Type of Draw
New Test 3001283  Autoimmune CNS Demyelinating Disease Reflexive Panel  CNS PAN

Click for Pricing

Additional Technical Information

Methodology: Semi-Quantitative Indirect Fluorescent Antibody
Performed: Wed
Reported: 1-8

Specimen Required: Collect: Serum Separator Tube (SST).
Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Hemolyzed, contaminated, or severely lipemic specimens.
Stability (collection to initiation of testing): After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles)

Reference Interval:

<table>
<thead>
<tr>
<th>Test Number</th>
<th>Components</th>
<th>Reference Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013320</td>
<td>Aquaporin-4 Receptor Antibody, IgG by IFA with Reflex to Titer, Serum</td>
<td>Less than 1:10</td>
</tr>
<tr>
<td>3001277</td>
<td>Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum</td>
<td>Less than 1:10</td>
</tr>
</tbody>
</table>

Interpretive Data: Refer to report.
See Compliance Statement D: www.aruplab.com/CS

Note: If Aquaporin-4 Receptor Antibody, IgG by IFA with Reflex to Titer, Serum is positive, then an Aquaporin-4 Receptor Antibody, IgG by IFA, Serum Titer will be added. If Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum is positive, then a Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Titer, IgG will be added. Additional charges apply.

CPT Code(s): 86255 x2; if reflexed, add 86256

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

2008665  Babesia Species by PCR  BABPCR

Specimen Required: Collect: Lavender (EDTA) or Pink (K2 EDTA).
Specimen Preparation: Transport 1 mL whole blood. (Min: 0.6 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Serum, plasma, and heparinized specimens.
Stability (collection to initiation of testing): Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 month
**BCL6 (3q27) Gene Rearrangement by FISH**

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday-Friday

**Reported:** 3-7 days

**Specimen Required:** Collect: Tumor tissue.

Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen. Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3-micron thick sections), positively charged slides in a tissue transport kit (ARUP supply #47808 recommended but not required), available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 2 slides) If sending precut slides, do not oven bake.

Storage/Transport Temperature: Room temperature or refrigerated. Ship in cooled container during summer months.

Remarks: Include surgical pathology report.

Unacceptable Conditions: Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.

Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Interpretive Data:**
Refer to report.
See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

**Beryllium Quantitative, Serum or Plasma**

**Methodology:** Quantitative Inductively Coupled Plasma-Mass Spectrometry

**Performed:** Varies

**Reported:** 3-8 days

**Specimen Required:** Collect: Royal Blue (no additive) or Royal Blue (EDTA).

Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an Acid Washed Transport Vial (ARUP supply #54350) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787. (Min: 0.4 mL)

Storage/Transport Temperature: Refrigerated. Also acceptable: Room temperature or frozen.

Unacceptable Conditions: Separator tubes.

Stability (collection to initiation of testing): Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 weeks

**Reference Interval:** By report

**CPT Code(s):** 83018

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
Quarterly HOTLINE: Effective February 19, 2019

**0099478**  Bismuth, Blood  BS B

**Performed:** Sun-Sat  
**Reported:** 1-3 days

**Specimen Required:** Patient Prep: Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician).  
Collect: Royal Blue (K$_2$EDTA or Na$_2$EDTA).  
Specimen Preparation: Transport 7 mL whole blood in the original collection tube. (Min: 0.5 mL)  
Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated.  
Unacceptable Conditions: Specimens collected in tubes other than Royal Blue (EDTA). Specimens transported in containers other than a Royal Blue (EDTA) tube or Trace Element-Free Transport Tube. Heparin anticoagulant. Clotted specimens.  
Stability (collection to initiation of testing): Ambient; Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** Effective February 19, 2019  
Less than or equal to 5.0 µg/L

**Interpretive Data:** Elevated results may be due to skin or collection-related contamination, including the use of a noncertified metal-free collection/transport tube. If contamination concerns exist due to elevated levels of blood bismuth, confirmation with a second specimen collected in a certified metal-free tube is recommended.

See Compliance Statement B: www.aruplab.com/CS

**HOTLINE NOTE:** Remove information found in the Note field. There is also a numeric map change associated with this test. Change the numeric map for component 0099478, Bismuth, Whole Blood from XXX to XX.X.

---

**2011436**  Bromide, Serum or Plasma  BROMIDE

**Specimen Required:** Collect: Plain Red, Lavender (K$_2$EDTA), Lavender (K$_3$EDTA), or Pink (K$_2$EDTA).  
Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
Storage/Transport Temperature: Refrigerated.  
Unacceptable Conditions: Whole blood, Gel Separator Tubes, Light Blue (Sodium Citrate), or Yellow (SPS or ACD Solution).  
Stability (collection to initiation of testing): Ambient: 1 week; Refrigerated: 1 weeks; Frozen: Indefinitely

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.  
Remove component 2011441, Bromide Dose  
Remove component 2011438, Bromide Route  
Remove component 2011437, Bromide Dose Frequency  
Remove component 2011439, Bromide Type of Draw
**2010357** Bupropion, Serum or Plasma

**Specimen Required:** Patient Prep: Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
- **Collect:** Plain red. Also acceptable: Lavender (K₂ or K₃EDTA) or pink (K₂EDTA).
- **Specimen Preparation:** Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)
- **Storage/Transport Temperature:** CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered
- **Unacceptable Conditions:** Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
- **Stability (collection to initiation of testing):** After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month

**Interpretive Data:** The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause mental confusion, cardiac abnormalities and seizures. Concentrations below 25 ng/mL may have no effect. This method does not quantify the major metabolite, hydroxybupropion.

See Compliance Statement B: www.aruplab.com/CS

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.
- Remove component 2011442, Bupropion Dose
- Remove component 2011444, Bupropion Route
- Remove component 2011443, Bupropion Dose Frequency
- Remove component 2011445, Bupropion Type of Draw

---

**0050301** C₁q Binding Assay

**Reference Interval:** Effective February 19, 2019
Less than or equal to 3.9 µEq/mL

**Interpretive Data:** Less than or equal to 3.9 µEq/mL is considered negative for circulating complement binding immune complexes. Circulating immune complexes may be found without any evident pathology and positive results do not necessarily implicate the immune complex in a disease process.

**HOTLINE NOTE:** There is a unit of measure change associated with this test.
Change the unit of measure for component 0050301, C₁q Binding Assay from µgE/mL to µg Eq/mL.
New Test 3001129  Capillary Malformation-Arteriovenous Malformation 2 (EPHB4) Sequencing

Available Now  
Click for Pricing

Additional Technical Information  
Patient History Form

Methodology: Polymerase Chain Reaction/Sequencing
Performed: Sun-Sat
Reported: Within 2 weeks

Specimen Required: Collect; Lavender (EDTA), Pink (K₂EDTA), or Yellow (ACD).
Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)
Storage/Transport Temperature: Refrigerated.
Stability (collection to initiation of testing): Ambient: 1 week; Refrigerated: 1 month; Frozen: 6 months

Interpretive Data:
Background Information for Capillary Malformation-Arteriovenous Malformation 2 (EPHB4) Sequencing:
Characteristics of Capillary Malformation-Arteriovenous Malformation (CM-AVM): Multifocal, randomly distributed, capillary malformations (CM) that may be associated with a fast-flow lesion (arteriovenous malformations [AVM] or arteriovenous fistula). Fast-flow lesions in the skin, muscle, bone, or central nervous system can cause life-threatening complications such as bleeding, congestive heart failure, or neurological consequences. Capillary malformation-arteriovenous malformation syndrome type 1 (CM-AVM1) is caused by RASA1 pathogenic variants; capillary malformation-arteriovenous malformation syndrome type 2 (CM-AVM2) is caused by EPHB4 pathogenic variants.
Incidence: Estimated at 1 in 20,000 for CM-AVM1 and 1 in 12,000 for CM-AVM2.
Inheritance: Autosomal dominant.
Penetran ce: 90-95 percent.
Cause: Pathogenic EPHB4 or RASA1 gene variants.
Gene Tested: EPHB4 only.
Clinical Sensitivity: Not well established, at least 15 percent.
Methodology: Bidirectional sequencing of all coding regions and intron-exon boundaries of the EPHB4 gene.
Analytical Specificity and Sensitivity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region variants, deep intronic variants, and large deletions/duplications will not be detected. Variants in genes other than EPHB4 are not detected.

See Compliance Statement C: www.aruplab.com/CS

CPT Code(s): 81479

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

0091352  Carbidopa and Levodopa Quantitative, Serum or Plasma  
SINEMET SP

Methodology: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

Specimen Required: Collect; Plain Red, Lavender (EDTA), or Pink (K₂EDTA).
Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube and flash freeze immediately with dry ice. (Min: 0.3 mL)
Storage/Transport Temperature: CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Unacceptable Conditions: Separator tubes. Thawed specimens.
Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 6 days
**2011450**  
**Carisoprodol and Meprobamate, Serum or Plasma, Quantitative**  
**CARIS SP**

**Performed:** Sun, Tue, Thu  
**Reported:** 1-4 days

**Specimen Required:** Collect: Serum Pre-dose (Trough) Draw - At a Steady State Concentration or Plasma Pre-dose (Trough) Draw - At a Steady State Concentration in Plain Red, Lavender (K$_2$EDTA), Lavender (K$_2$EDTA), or Pink (K$_2$EDTA).  
**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
**Storage/Transport Temperature:** Refrigerated.  
**Unacceptable Conditions:** Whole blood, Gel Separator Tubes, Light Blue (Sodium Citrate), or Yellow (SPS or ACD Solution).  
**Stability (collection to initiation of testing):** Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 months

**Interpretive Data:** The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects may include drowsiness, dizziness and headache.

See Compliance Statement B: [www.aruplab.com/CS](http://www.aruplab.com/CS)

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.  
Remove component 2011451, Carisoprodol Dose  
Remove component 2011452, Carisoprodol Dose Frequency
Remove component 2011454, Carisoprodol Type of Draw

**2012219**  
**Carisoprodol and Meprobamate, Urine, Quantitative**  
**CARIS U**

**Performed:** Sun, Tue, Thu  
**Reported:** 1-6 days
New Test 3001132 Capillary Malformation-Arteriovenous Malformation (EPHB4 and RASA1) Sequencing, and (RASA1) Deletion/Duplication

CMAVM PAN

Available Now
Click for Pricing

Methodology: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification
Performed: Sun- Sat
Reported: Within 1 month

Specimen Required: Collect: Lavender (EDTA), Pink (K,EDTA), or Yellow (ACD).
Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)
Storage/Transport Temperature: Refrigerated.
Stability (collection to initiation of testing): Ambient: 1 week; Refrigerated: 1 month; Frozen: 6 months

Interpretive Data:
Background Information for Capillary Malformation-Arteriovenous Malformation (EPHB4 and RASA1) Sequencing and (RASA1) Deletion/Duplication:
Characteristics: Multifocal, randomly distributed, capillary malformations (CM) of the skin that may be associated with a fast-flow lesion (arteriovenous malformations [AVM] or arteriovenous fistula). Fast-flow lesions in the skin, muscle, bone, or central nervous system can cause life-threatening complications such as bleeding, congestive heart failure, or neurological consequences. Capillary malformation-arteriovenous malformation syndrome type 1 (CM-AVM1) is caused by RASA1 pathogenic variants; capillary malformation-arteriovenous malformation syndrome type 2 (CM-AVM2) is caused by EPHB4 pathogenic variants.
Incidence: Estimated at 1 in 20,000 for CM-AVM1 and 1 in 12,000 for CM-AVM2.
Inheritance: Autosomal dominant; approximately one-third of RASA1 pathogenic variants are de novo.
Penetrance: 90-95 percent.
Cause: Pathogenic RASA1 and EPHB4 variants.
Clinical Sensitivity: Not well-established, but at least 65 percent.
Methodology: Bidirectional sequencing of all coding regions and intron-exon boundaries of the EPHB4 and RASA1 genes; Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large RASA1 deletions/duplications.
Analytical Specificity and Sensitivity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region variants and deep intronic variants will not be detected. Large deletions/duplications will not be detected in EPHB4. The breakpoints of large RASA1 deletions/duplications will not be determined.

See Compliance Statement C: www.aruplab.com/CS

CPT Code(s): 81479

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

0020414 Creatine Kinase Isoenzymes CKISO

Performed: Sun-Sat
Reported: 2-3 days

Specimen Required: Collect: Serum Separator Tube (SST) or Plain Red.
Specimen Preparation: Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Storage/Transport Temperature: Frozen.
Unacceptable Conditions: Specimens preserved in citrate, EDTA, fluoride, heparin, or iodoacetate. Grossly hemolyzed specimens.
Stability (collection to initiation of testing): After separation from cells: Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 1 month (avoid repeated freeze/thaw cycles)

Note: This test will detect CK macroenzymes.

0090060 Cyanide CYAN

Performed: Sun, Tue, Fri
Reported: 1-5 days
New Test

**3001304**

**DDIT3 (CHOP) (12q13) Gene Rearrangement by FISH**

**DDIT3 FISH**

---

**Additional Technical Information**

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday-Friday

**Reported:** 3-7 days

**Specimen Required:** Collect: Tumor tissue.

**Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (4-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #7808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended but not required). (Min 2 slides).

**Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.

**Remarks:** Include surgical pathology report.

**Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B4 or B5).

**Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** By report

**Interpretive Data:** Refer to report.

See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

---

2011487

Desipramine, Serum or Plasma by Tandem Mass Spectrometry

**DESIPRAMIN**

**Specimen Required:** Collect: Serum Pre-dose (Trough) Draw - At a Steady State Concentration or Plasma Pre-dose (Trough) Draw - At a Steady State Concentration in Plain Red, Lavender (K,EDTA), Lavender (K,EDTA), or Pink (K,EDTA).

**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

**Storage/Transport Temperature:** Refrigerated.

**Unacceptable Conditions:** Whole blood. Gel Separator Tubes, Light Blue (Sodium Citrate), or Yellow (SPS or ACD Solution).

**Stability (collection to initiation of testing):** Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 6 months

**Interpretive Data:** The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause anticholinergic effects, drowsiness and cardiac abnormalities.

See Compliance Statement B: www.aruplab.com/CS

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test. Remove component 2011492, Desipramine Dose
Remove component 2011489, Desipramine Route
Remove component 2011488, Desipramine Dose Frequency
Remove component 2011490, Desipramine Type of Draw
### Specimen Required:
- **Patient Prep:** Collect specimen 8-12 hours (no earlier than 6 hours) after administration of oral dose.
- **Collect:** Plain red. Also acceptable: Green (sodium or lithium heparin).
- **Specimen Preparation:** Remove serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- **Storage/Transport Temperature:** Frozen. Also acceptable: Refrigerated.
- **Remarks:** Refrigerated.
- **Unacceptable Conditions:** Specimens collected in sodium fluoride, potassium oxalate or separator tubes. Hemolyzed specimens.
- **Stability (collection to initiation of testing):**
  - After separation from cells: Ambient: 8 hours; Refrigerated: 48 hours; Frozen: 1 week

### Drug Screen (Nonforensic), Serum
- **Performed:** Sun, Tue-Sat
- **Reported:** 1-6 days

**Interpretive Data:** The following drugs or drug classes may be detected: acetaminophen, barbiturates, benzodiazepines, carbamazepine, carisoprodol, disopyramide, meprobamate, phenytoin, primidone, salicylate, theophylline, tricyclic and other antidepressants.

See Compliance Statement B: www.aruplab.com/CS

### Drug Screen (Nonforensic), Urine, Qualitative
- **Performed:** Sun, Tue-Sat
- **Reported:** 1-6 days

**Interpretive Data:** The following drugs or drug classes may be detected:

- Acetaminophen, barbiturates, benzodiazepines, carbamazepine, carisoprodol, chlorpheniramine, cocaine and metabolites, diphenhydramine, ethchlorvynol, ibuprofen, lidocaine, meprobamate, narcotics and synthetics, phencyclidine, phenothiazines, phenytoin, primidone and metabolites, pyrilamine, salicylate, sympathomimetic amines, theophylline, tricyclic and other antidepressants.

See Compliance Statement B: www.aruplab.com/CS
**New Test**

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Description</th>
<th>Methodology</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Test</td>
<td>EGFR Gene Amplification by FISH</td>
<td>Fluorescence in situ Hybridization</td>
</tr>
<tr>
<td>3001310</td>
<td>EGFR FISH</td>
<td></td>
</tr>
</tbody>
</table>

**Specimen Required:**
- **Collect:** Tumor tissue.
- **Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (4-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended but not necessary). (Min 2 slides)
- **Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
- **Remarks:** Include surgical pathology report
- **Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5).
- **Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** By report

**Interpretive Data:** Refer to report.

See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88377

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

**2002440**

*EGFR Mutation Detection by Pyrosequencing*

**Performed:** DNA isolation: Sun-Sat
- Assay: Tue, Thu, Sat

**Reported:** 6-14 days

**2007862**

*Ehrlichia and Anaplasma Species by PCR*

**Specimen Required:**
- **Collect:** Lavender (EDTA) or Pink (K$_2$EDTA).
- **Specimen Preparation:** Transport 1 mL whole blood. (Min: 0.6 mL)
- **Storage/Transport Temperature:** Refrigerated.
- **Unacceptable Conditions:** Serum, plasma, and heparinized specimens.
- **Stability (collection to initiation of testing):** Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 week

**0051002**

*Ehrlichia chaffeensis Antibodies, IgG & IgM by IFA*

**Specimen Required:**
- **Collect:** Serum separator tube.
- **Specimen Preparation:** Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as acute or convalescent.
- **Storage/Transport Temperature:** Refrigerated.
- **Unacceptable Conditions:** Contaminated, hemolyzed, or severely lipemic specimens.
- **Stability (collection to initiation of testing):** After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
**0051004**  
*Ehrlichia chaffeensis* Antibody, IgG by IFA  

**Specimen Required:** Collect; Serum separator tube.  
**Specimen Preparation:** Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL) Parallel testing is preferred and convalescent specimens **must** be received within 30 days from receipt of the acute specimens. **Mark specimens plainly as acute or convalescent.**  
**Storage/Transport Temperature:** Refrigerated.  
**Unacceptable Conditions:** Contaminated, hemolyzed, or severely lipemic specimens.  
**Stability (collection to initiation of testing):** After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

**0051003**  
*Ehrlichia chaffeensis* Antibody, IgM by IFA  

**Specimen Required:** Collect; Serum separator tube.  
**Specimen Preparation:** Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL) Parallel testing is preferred and convalescent specimens **must** be received within 30 days from receipt of the acute specimens. **Mark specimens plainly as acute or convalescent.**  
**Storage/Transport Temperature:** Refrigerated.  
**Unacceptable Conditions:** Contaminated, hemolyzed, or severely lipemic specimens.  
**Stability (collection to initiation of testing):** After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

**2007909**  
*Ethyl Glucuronide and Ethyl Sulfate, Urine, Quantitative*  

**Performed:** Sun, Tue-Wed, Fri-Sat  
**Reported:** 1-6 days

**New Test**  
**3001305**  
*EWSR1 (22q12) Gene Rearrangement by FISH*  

**Methodology:** Fluorescence in situ Hybridization  
**Performed:** Monday-Friday  
**Reported:** 3-7 days

**Specimen Required:** Collect; Tumor tissue.  
**Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (4-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended but not necessary).  
**Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.  
**Remarks:** Include surgical pathology report.  
**Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.  
**Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Interpretive Data:**  
Refer to report.  
See Compliance Statement A: www.arulab.com/CS

**CPT Code(s):** 88366

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
**2013694** Explify Respiratory Pathogens by Next Generation Sequencing **RESP NGS**

**HOTLINE NOTE:** There is a price change associated with this test. Please contact ARUP Client Services at (800) 522-2787 for additional information.

**2011776** Fentanyl and Metabolite, Serum or Plasma, Quantitative **CDCO FNSP**

**Specimen Required:** Collect: Plain Red, Lavender (K$_2$EDTA), Lavender (K$_2$EDTA), Green (Sodium Heparin), Gray (Potassium Oxalate/Sodium Fluoride), or Pink (K$_2$EDTA).

**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 4 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 2 mL)

**Storage/Transport Temperature:** Refrigerated.

**Unacceptable Conditions:** Whole blood. Serum separator tubes, Light Blue (Sodium Citrate), or Plasma separator tubes. Specimens exposed to repeated freeze/thaw cycles.

**Stability (collection to initiation of testing):** Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.

Remove component 2011778, Fentanyl Dose
Remove component 2011780, Fentanyl Route
Remove component 2011779, Fentanyl Dose Frequency
Remove component 2011781, Fentanyl Type of Draw

**0090003** Flecainide **FLEC**

**Performed:** Mon, Thu, Sat

**Reported:** 1-5 days

**Interpretive Data:** Toxic concentrations may cause cardiac abnormalities, hypotension and seizure.

See Compliance Statement B: www.aruplab.com/CS
New Test
Available Now
Click for Pricing

Additional Technical Information

Methodology: Polymerase Chain Reaction
Performed: DNA isolation: Sun-Sat
Assay: Mon, Wed, Fri
Reported: 2-7 days

Specimen Required: Collect: Lavender (EDTA) or bone marrow (EDTA).
Specimen Preparation: Whole Blood: Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Transport 3 mL bone marrow. (Min: 1 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: FFPE tumor tissue. Fresh Tissue. Clotted or grossly hemolyzed specimens.
Stability (collection to initiation of testing): Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable

Interpretive Data: Refer to report.
See Compliance Statement B: www.aruplab.com/CS

CPT Code(s): 81245, 81246

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.
**FOXI1 (FKHR) (13q14) Gene Rearrangement by FISH**

**FKHR_FISH**

**Additional Technical Information**

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday-Friday

**Reported:** 3-7 days

**Specimen Required:**
- **Collect:** Tumor tissue.
- **Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (4-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended, but not necessary). (Min. 2 slides)
- **Storage/Transport Temperature:** Room temperature or refrigerated. Ship in cooled container during summer months.
- **Remarks:** Include surgical pathology report.
- **Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.

**Reference Interval:** By report

**Interpretive Data:**
- Refer to report.
- See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

---

**Gabapentin**

**0090057**

**Performed:** Mon, Wed-Sat

**Reported:** 1-4 days

**Interpretive Data:** Pharmacokinetics of gabapentin vary widely among patients, particularly those with compromised renal function. Adverse effects may include somnolence, dizziness, ataxia, and fatigue.

See Compliance Statement B: www.aruplab.com/CS

---

**Gabapentin, Urine**

**2012227**

**Performed:** Mon, Wed, Sat

**Reported:** 1-6 days
# New Test 3001267

**Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody, IgG by IFA with Reflex to Titer, CSF**

**GABA-B CSF**

**Click for Pricing**

<table>
<thead>
<tr>
<th>Methodology:</th>
<th>Semi-Quantitative Indirect Fluorescent Antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performed:</td>
<td>Wed</td>
</tr>
<tr>
<td>Reported:</td>
<td>1-8 days</td>
</tr>
</tbody>
</table>

**Specimen Required:**
- **Collect:** CSF.
- **Specimen Preparation:** Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. *(Min: 0.15 mL)*
- **Storage/Transport Temperature:** Refrigerated.
- **Unacceptable Conditions:** Hemolyzed, contaminated, or severely lipemic specimens.
- **Stability (collection to initiation of testing):** Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

**Reference Interval:** Less than 1:1

**Interpretive Data:** Gamma-aminobutyric acid receptor, type B (GABA-BR) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes GABA-BR transfected cell lines for the detection and semi-quantification of GABA-BR IgG antibody.

See Compliance Statement D: www.aruplab.com/CS

**Note:** If Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody, IgG by IFA with Reflex to Titer, CSF is positive, then a Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody Titer, IgG, CSF is performed. Additional charges apply.

**CPT Code(s):** 86255; if reflexed, add 86256

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
### New Test 3001270  
**Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody, IgG by IFA with Reflex to Titer, Serum**  
GABA-B SER  
Click for Pricing  

**Methodology:** Semi-Quantitative Indirect Fluorescent Antibody  
**Performed:** Wed  
**Reported:** 1-8 days  

**Specimen Required:**  
- **Collect:** Serum Separator Tube (SST) or Plain Red.  
- **Specimen Preparation:** Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)  
- **Storage/Transport Temperature:** Refrigerated.  
- **Unacceptable Conditions:** Hemolyzed, contaminated, or severely lipemic specimens.  
- **Stability (collection to initiation of testing):** Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month  

**Reference Interval:** Less than 1:10  

**Interpretive Data:** Gamma-aminobutyric acid receptor, type B (GABA-BR) antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune encephalitis.  

This indirect fluorescent antibody assay utilizes GABA-BR transfected cell lines for the detection and semi-quantification of GABA-BR IgG antibody.  

See Compliance Statement D: www.aruplab.com/CS  

**Note:** If Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody, IgG by IFA with Reflex to Titer, Serum is positive, then a Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody Titer, IgG, Serum is performed. Additional charges apply.  

**CPT Code(s):**  
- 86255; if reflexed, add 86256  

New York DOH approval pending. Call for status update.  

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

### New Test 3001284  
**Herpesvirus 6 Antibody, IgM by IFA, Serum**  
HHV6 AB M  
Click for Pricing  

**Methodology:** Semi-Quantitative Indirect Fluorescent Antibody  
**Performed:** Varies  
**Reported:** 3-7 days  

**Specimen Required:**  
- **Collect:** Plain Red or Serum Separator Tube (SST).  
- **Specimen Preparation:** Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL)  
- **Storage/Transport Temperature:** Refrigerated. Also acceptable: Room temperature or frozen.  
- **Stability (collection to initiation of testing):** Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 month  

**CPT Code(s):**  
- 86790  

New York DOH Approved.  

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
New Test

**3001393**

**HLA-B*58:01 Genotyping, Allopurinol Hypersensitivity**

**Methodology:** Polymerase Chain Reaction/Sequence Specific Oligonucleotide Probe Hybridization

**Performed:** Mon-Fri

**Reported:** 3-7 days

**Specimen Required:**
- **Collect:** Lavender (EDTA), Pink (K<sub>2</sub>EDTA), or Yellow (ACD Solution A or B).
- **Specimen Preparation:** Transport 5 mL whole blood. (Min: 3 mL)
- **Storage/Transport Temperature:** Refrigerated.
- **Unacceptable Conditions:** Specimens collected in green (sodium or lithium heparin).

**Reference Interval:** By report

**Interpretive Data:**
**Characteristics:** Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. It inhibits xanthine oxidase, a key enzyme involved in uric acid formation. However, allopurinol is one of the most common causes of life-threatening severe cutaneous adverse reactions (SCAR), which include drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The presence of HLA-B*58:01 allele shows strong association with allopurinol-induced SCAR, including TEN and SJS. Although allopurinol-induced SCAR is rare with an estimated risk of 0.1-0.4 percent in allopurinol users, the severity can be high, with a mortality rate of up to 25 percent. Symptoms include rash, combined with eosinophilia, leukocytosis, fever, hepatitis and progressive kidney failure. Due to the severity of adverse reactions, it is recommended to test for the HLA-B*58:01 allele prior to initiation of the drug.

**Incidence:** HLA-B*58:01 allele frequency varies by ethnicity. In the US population, the highest incidence at 5.3 percent is found in Asians, 3.8 percent in African Americans, 1.45 percent in Native Hawaiians or Pacific Islanders, 1.35 percent in Hispanics, 1.19 percent in American Indians or Alaska Natives and 0.8 percent in Caucasians. Frequencies may be higher in other countries, up to 20 percent in Singapore, Taiwan and among Han Chinese, 15.4 percent in India, 14.2 percent in Hong Kong, 12 percent in China and Korea, 11 percent in Indonesia.

**Cause:** Allopurinol-induced SCAR, including SJS and TEN, is strongly associated with the presence of one or two copies of HLA-B*58:01 allele. The mechanism is immune mediated and involves direct interactions between the allopurine metabolite oxypurinol, and HLA-B*58:01, which may result in drug-induced changes in peptide presentation, allowing activation of self-reactive T lymphocytes.

**Alleles tested:** HLA-B*58:01 allele.

**Clinical Sensitivity and Specificity:** 71 percent sensitivity and 92 percent specificity, overall mean values from pooled populations (Yu KH at al, Int J Rheum Dis 2017). Higher in populations with increased HLA-B*58:01 allele frequency.

**Methodology:** PCR followed by Sequence Specific Oligonucleotide Probe Hybridization of HLA-B locus.

**Analytical Sensitivity and Specificity:** Greater than 99 percent.

**Limitations:** Copy number of HLA-B*58:01 will not be reported. Other genetic and non-genetic factors that influence allopurinol hypersensitivity are not evaluated. Other rare, or novel alleles may occur which may lead to false positive or false negative results.

**CPT Code(s):** 81381

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

**2010292**

**Hypoglycemia Panel, Sulfonylureas Qualitative, Serum or Plasma**

**Perform:*** Sun, Tue, Thu

**Reported:** 1-6 days

**Interpretive Data:** This assay is used to evaluate hypoglycemia that may be caused from the ingestion of sulfonylurea drugs. Hypoglycemic drugs are detected (present) in this assay if the drug concentration is greater than the limit of detection (cut-off). The presence of hypoglycemic drug(s) indicates a recent ingestion.

See Compliance Statement B: www.aruplab.com/CS
**Ibuprofen Quantitative, Serum or Plasma**

**Methodology:** Quantitative High Performance Liquid Chromatography/Tandem Mass Spectrometry

**Specimen Required:** Collect: Plain Red. Also acceptable: Lavender (EDTA) or Pink (K<sub>2</sub>EDTA).

**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.21 mL)

**Storage/Transport Temperature:** Refrigerated. Also acceptable: Room temperature or frozen.

**Unacceptable Conditions:** Separator tubes

**Stability (collection to initiation of testing):** Ambient: 15 days; Refrigerated: 15 days; Frozen: 15 days

---

**IGH-BCL2 Fusion, t(14;18) by FISH**

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday–Friday

**Reported:** 3–7 days

**Specimen Required:** Collect: Tumor tissue.

**Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin-embed specimen. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (3-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit is recommended by not necessary). (Min: 2 slides)

**Storage/Transport Temperature:** Room temperature or refrigerated. Ship in cooled container during summer months.

**Remarks:** Include surgical pathology report.

**Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.

**Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** By report

**Interpretive Data:** Refer to report.

See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
New Test 3001306 IGH-CCND1 Fusion, t(11;14) by FISH IGHCC_FISH

Click for Pricing

Additional Technical Information

Test not New York DOH approved at any laboratory. An approved NPL form must accompany specimen.

Methodology: Fluorescence in situ Hybridization
Performed: Monday-Friday
Reported: 3-7 days

Specimen Required: Collect: Tumor tissue.
Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed specimen. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (3-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit is recommended but not necessary). (Min: 2 slides)
Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Remarks: Include surgical pathology report.
Unacceptable Conditions: Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.
Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable.

Reference Interval: By report

Interpretive Data:
Refer to report.
See Compliance Statement A: www.aruplab.com/CS

CPT Code(s): 88366

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.
New Test 3001299  **IGH-MYC Fusion t(8;14) by FISH**

**IGHMC FISH**

**Additional Technical Information**

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday-Friday

**Reported:** 3-7 days

**Specimen Required:**
- **Collect:** Tumor tissue.
- **Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin-embed specimen. Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3-micron thick sections) positively charge slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit is recommended but not necessary). (Min: 2 slides) If sending precut slides, do not oven bake.
- **Storage/Transport Temperature:** Room temperature or refrigerated. Ship in cooled container during summer months.
- **Remarks:** Include surgical pathology report.
- **Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.

**Reference Interval:** By report

**Interpretive Data:**
Refer to report.
See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

---

**0050667 Immune Complex Panel**

**C1Q/RAJI**

<table>
<thead>
<tr>
<th>Available Separately</th>
<th>Components</th>
<th>Reference Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>0050301</td>
<td>C1q Binding Assay</td>
<td>Effective February 19, 2019</td>
</tr>
<tr>
<td>0050302</td>
<td>Raji Cell Immune Complex Assay</td>
<td>By report</td>
</tr>
</tbody>
</table>

**Interpretive Data:** Less than or equal to 3.9 µg Eq/mL is considered negative for circulating complement binding immune complexes. Circulating immune complexes may be found without any evident pathology and positive results do not necessarily implicate the immune complex in a disease process. Many autoimmune disorders, chronic infections, and malignancies are associated with circulating immune complexes. Quantitation of immune complexes assists in staging immunologic disorders.

See Compliance Statement A: www.aruplab.com/CS

**HOTLINE NOTE:** There is a unit of measure change associated with this test.
Change the unit of measure for component 0050301, C1q Binding Assay from µgE/mL to µg Eq/mL.
**2012084**  
*JAK2 Gene, V617F Mutation, Qualitative with Reflex to CALR (Calreticulin) Exon 9 Mutation Analysis by PCR with Reflex to MPL Mutation Detection*

**Methodology:**  
Polymerase Chain Reaction/Capillary Electrophoresis/Capillary Electrophoresis

**Performed:**  
DNA Isolation: Sun-Sat  
Assay: Mon, Wed, Fri

**Reported:**  
3-6 days

**Note:** If JAK2 V617F is reported as “Not Detected” then CALR Exon 9 Mutation Analysis by PCR will be added. If CALR is reported as “Not Detected,” then MPL Mutation Detection will be added. Additional charges apply.

**0040105**  
*Kleihauer-Betke Stain for Fetal Hemoglobin*

**Specimen Required:**  
Collect: Lavender (EDTA) or Pink (K2EDTA).  
Specimen Preparation: Transport 3 mL whole blood. (Min: 0.5 mL)  
Storage/Transport Temperature: Refrigerated.

**Unacceptable Conditions:** Specimens collected after Rh immunoglobulin administered, Cord or Fetal blood, Clotted specimens.

**Stability (collection to initiation of testing):** Ambient: 72 hours; Refrigerated: 72 hours; Frozen: Unacceptable

**0050021**  
*LDL Subclasses*

**Specimen Required:**  
Patient Prep: Patient should be fasting for 12 hours prior to collection.  
Collect: Lavender (EDTA), Pink (K2EDTA), Plain Red, or Serum Separator Tube (SST).  
Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.2 mL)  
Storage/Transport Temperature: Refrigerated.

**Unacceptable Conditions:** Heparinized plasma. Specimens from patients receiving heparin. Grossly hemolyzed specimens.

**Stability (collection to initiation of testing):** Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: Unacceptable

**2008894**  
*Lung Cancer Panel*

**HOTLINE NOTE:** There is a reflexive pattern change associated with this test.  
Remove reflex to 2008418, ROSI by FISH  
Add reflex to 3001308, ROSI, FISH

**2008895**  
*Lung Cancer Panel with KRAS*

**HOTLINE NOTE:** There is a reflexive pattern change associated with this test.  
Remove reflex to 2008418, ROSI by FISH  
Add reflex to 3001308, ROSI, FISH
0099272 Manganese, Whole Blood MANG WB

**Performed:** Sun-Sat  
**Reported:** 1-3 days

**Specimen Required:**  
**Patient Prep:** Diet, medication, and nutritional supplements may introduce interfering substances. Patient should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician).  
**Collect:** Royal Blue (K₂EDTA or Na₂EDTA).  
**Specimen Preparation:** Transport 7 mL whole blood in the original collection tube. (Min: 0.5 mL)  
**Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated.  
**Unacceptable Conditions:** Specimens collected in tubes other than Royal Blue (EDTA). Specimens transported in containers other than a Royal Blue (EDTA) tube or Trace Element-Free Transport Tube. Heparin anticoagulant. Clotted specimens.  
**Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Interpretive Data:** Elevated results may be due to skin or collection-related contamination, including the use of a noncertified metal-free collection/transport tube. If contamination concerns exist due to elevated levels of blood manganese, confirmation with a second specimen collected in a certified metal-free tube is recommended.

See Compliance Statement B: www.aruplab.com/CS

**HOTLINE NOTE:** Remove information found in the Note field. There is also a numeric map change associated with this test.  
Change the numeric map for component 0099272, Manganese, Blood from XXXX.X to XXX.X.

2014704 Maternal T Cell Engraftment in SCID, Maternal Specimen SCID-MAT

**Time Sensitive**

**New York Clients:** Direct Submission Instructions

**Specimen Required:**  
**Collect:** Lavender (EDTA), Pink (K₂EDTA), or Yellow (ACD Solution A).  
**New York State Clients:** Lavender (EDTA). **Collect Monday-Thursday only.**  
**Specimen Preparation:** Transport 3 mL whole blood. (Min: 1 mL)  
**New York State Clients:** Transport 14 mL whole blood. (Min: 6 mL). **Do not send to ARUP Laboratories.** Specimens must be received at performing laboratory within 24 hours of collection. For specimen requirements and direct submission instructions please contact ARUP Referral Testing at (800) 242-2787, ext. 5145.  
**Storage/Transport Temperature:** Refrigerated.  
**Stability (collection to initiation of testing):** Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable  
**New York State Clients:** Ambient: 24 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
### New Test 3001301 MDM2 Gene Amplification by FISH MDM2_FISH

**Additional Technical Information**

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday-Friday

**Reported:** 3-7 days

**Specimen Required:** Collect: Tumor tissue.

**Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue. Protect paraffin block from excessive heat. Transport block or 5 unstained (4-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended but not necessary). (Min 2 slides)

**Storage/Transport Temperature:** Room temperature or refrigerated. Ship in cooled container during summer months.

**Remarks:** Include surgical pathology report.

**Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.

**Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** By report

**Interpretive Data:** Refer to report.

See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):** 88377

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

### New Test 3001158 Melatonin Quantitative, Serum or Plasma MELATON SP

**Methodology:** Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

**Performed:** Varies

**Reported:** 7-10 days

**Specimen Required:** Collect: Plain Red, Lavender (EDTA), or Pink (K$_2$EDTA).

**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)

**Storage/Transport Temperature:** Refrigerated. Also acceptable: Room temperature or frozen.

**Unacceptable Conditions:** Separator tubes.

**Stability (collection to initiation of testing):** Ambient: 2 weeks; Refrigerated: 1 month; Frozen: 1 year

**Reference Interval:** By report

**CPT Code(s):** 80375 (Alt code: G0480)

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
### Meprobamate, Serum or Plasma, Quantitative

**Performed:** Sun, Tue, Thu  
**Reported:** 1-4 days

**Specimen Required:** Collect: Plain Red, Lavender (K$_2$EDTA), Lavender (K$_3$EDTA), or Pink (K$_2$EDTA).  
**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
**Storage/Transport Temperature:** Refrigerated.  
**Unacceptable Conditions:** Whole blood, Gel Separator Tubes, Light Blue (Sodium Citrate), or Yellow (SPS or ACD Solution).  
**Stability (collection to initiation of testing):** Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 months

**Interpretive Data:** The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects may include drowsiness, dizziness and headache.

See Compliance Statement B: www.arulab.com/CS

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test. Remove component 2011522, Meprobamate Dose  
Remove component 2011524, Meprobamate Route  
Remove component 2011523, Meprobamate Dose Frequency  
Remove component 2011525, Meprobamate Type of Draw

### MET Gene Amplification by FISH

**New Test** 3001313  
**Methodology:** Fluorescence in situ Hybridization  
**Performed:** Varies  
**Reported:** 3-7 days

**Specimen Required:** Collect: Tumor tissue.  
**Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed tumor tissue. Transport tissue block or 4 unstained, consecutively cut, 5-micron thick sections, mounted on positively charged glass slides. (Min: 4 slides) Protect paraffin block and/or slides from excessive heat.  
**Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated.  
**Remarks:** Include surgical pathology report with reason for referral. The laboratory will not reject specimens that arrive without a pathology report but will hold the specimen until this information is received.  
**Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.  
**Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** By report

**Interpretive Data:** Refer to report.  
See Compliance Statement A: www.arulab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
2011539  Mexiletine, Serum or Plasma  MEXILE

Performed:  Mon, Thu, Sat
Reported:  1-5 days

Specimen Required:  Collect: Serum Pre-dose (Trough) Draw - At a Steady State Concentration or Plasma Pre-dose (Trough) Draw - At a Steady State Concentration in Plain Red, Lavender (K$_2$EDTA), Lavender (K$_3$EDTA), or Pink (K$_3$EDTA).
Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Whole blood, Gel Separator Tubes, Light Blue (Sodium Citrate), or Yellow (SPS or ACD Solution).
Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 5 days; Frozen: 2 months

HOTLINE NOTE:  Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.
Remove component 2011540, Mexiletine Dose
Remove component 2011542, Mexiletine Route
Remove component 2011541, Mexiletine Dose Frequency
Remove component 2011543, Mexiletine Type of Draw

0051740  Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR  MSI PCR

Performed:  DNA isolation: Sun-Sat
Assay:  Sun, Tue, Thu
Reported:  10-20 days

2005545  MPL Mutation Detection by Capillary Electrophoresis  MPL

Methodology:  Polymerase Chain Reaction/Capillary Electrophoresis

Specimen Required:  Collect: Lavender (EDTA).
Specimen Preparation: Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Plasma or serum. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens.
Stability (collection to initiation of testing): Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable

Note:  The test will detect $MPL$ mutations W515K, W515L, W515A, and S505N.
New Test  
**3001300**  
MYC (8q24) Gene Rearrangement by FISH  
MYC FISH  

**Click for Pricing**

**New Test**  
**3001300**  
MYC (8q24) Gene Rearrangement by FISH  
MYC FISH  

**Click for Pricing**

**Additional Technical Information**

**Methodology:**  
Fluorescence in situ Hybridization

**Performed:**  
Monday-Friday

**Reported:**  
3-7 days

**Specimen Required:**  
Collect: Tumor tissue.

Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed specimen. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (3-micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit is recommended but not necessary). (Min: 2 slides)

Specimen Storage/Transport Temperature: Room temperature or refrigerated. Ship in cooled container during summer months.

Remarks: Include surgical pathology report.

Unacceptable Conditions: Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.

Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:**  
By report

**Interpretive Data:**  
Refer to report.

See Compliance Statement A: www.aruplab.com/CS

**CPT Code(s):**  
88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
**New Test**  
*3001307*  
**MYCN (N-MYC) Gene Amplification by FISH**  
**NMYC_FISH**

### Additional Technical Information

**Methodology:** Fluorescence in situ Hybridization  
**Performed:** Monday-Friday  
**Reported:** 3-7 days

**Specimen Required:**  
- **Collect:** Tumor tissue.  
- **Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue. Protect paraffin block from excessive heat. Transport block or 5 unstained (4 micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended but not necessary). (Min 2 slides)  
- **Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.  
- **Remarks:** Include surgical pathology report.  
- **Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.

**Stability (collection to initiation of testing):**  
- Ambient: Indefinitely  
- Refrigerated: Indefinitely  
- Frozen: Unacceptable

**Interpretive Data:**  
Refer to report.  
See Compliance Statement A: [www.aruplab.com/CS](http://www.aruplab.com/CS)

**CPT Code(s):** 88377

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

---

**2010359**  
**Mycophenolic Acid and Metabolites**  
**MPA MET**

**Performed:** Sun-Sat  
**Reported:** 1-3 days
New Test  3001277  Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum

Methodology:  Semi-Quantitative Indirect Fluorescent Antibody
Performed:  Wed
Reported:  1-8 days

Specimen Required:  Collect: Serum Separator Tube (SST) or Plain Red.
                   Specimen Preparation: Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
                   Storage/Transport Temperature: Refrigerated.
                   Unacceptable Conditions: Hemolyzed, contaminated, or severely lipemic specimens.
                   Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval:  Less than 1:10

Interpretive Data: Myelin oligodendrocyte glycoprotein (MOG) antibody is found in a subset of patients with neuromyelitis optica spectrum disorders, including optic neuritis and transverse myelitis, brainstem encephalitis, and acute disseminated encephalomyelitis. Persistence of antibody positivity may be associated with a relapsing course. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of CNS demyelinating disease or autoimmune encephalitis.

This indirect fluorescent antibody assay utilizes full-length MOG transfected cell lines for the detection and semi-quantification of MOG IgG antibody.

See Compliance Statement D: www.aruplab.com/CS

Note: If Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum is positive, then a Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Titer, IgG is performed. Additional charges apply.

CPT Code(s):  86255; if reflexed, add 86256

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

New Test  3001291  Neisseria gonorrhoeae Antibody by CF, Serum

Methodology:  Semi-Quantitative Complement Fixation
Performed:  Varies
Reported:  3-7 days

Specimen Required:  Collect: Plain Red or Serum Separator Tube (SST).
                   Specimen Preparation: Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
                   Storage/Transport Temperature: Refrigerated. Also acceptable: Room temperature or frozen.
                   Stability (collection to initiation of testing): Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 month

CPT Code(s):  86609

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.
Nickel, Serum

Performed: Sun-Sat
Reported: 1-3 days

Specimen Required:
- Patient Prep: Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician).
- Collect: Royal Blue (no additive).
- Specimen Preparation: Centrifuge; do not allow serum to remain on cells. Transfer 2 mL serum to an ARUP Trace Element-Free Transport Tube (ARUP supply #43116) within 2 hours of collection. Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 0.5 mL)
- Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated or frozen.
- Unacceptable Conditions: Specimens collected in tubes other than Royal Blue (no additive). Specimens transported in containers other than a Royal Blue (no additive) tube or Trace Element-Free Transport Tube. Heparin anticoagulant. Specimens that are not separated from the red cells or clot within 2 hours.

Interpretive Data: Elevated results may be due to skin or collection-related contamination, including the use of a noncertified metal-free collection/transport tube. If contamination concerns exist due to elevated levels of serum nickel, confirmation with a second specimen collected in a certified metal-free tube is recommended.

Serum nickel testing is intended to detect potentially toxic exposure. See Compliance Statement B: www.aruplab.com/CS

Organic Acids, Plasma

Methodology: Quantitative Gas Chromatography/Mass Spectrometry

HOTLINE NOTE: There is a component change associated with this test.
- Add component 3001293, Glutaric Acid, Plasma
- Remove component 0081052, Citric Acid, Plasma

Ova and Parasite Exam, Body Fluid or Urine

Specimen Required:
- Patient Prep: Urine: If S. haematobium is suspected, collect at midday or 24-hour collection in a container without preservative. Peak egg excretion occurs between noon and 3 p.m.
- Collect: Body fluid, CSF, or urine.
- Specimen Preparation: Transfer 4 mL body fluid, CSF, or urine to an ARUP Standard Transport Tube (ARUP Supply #46307). (Min: 1 mL)
- Storage/Transport Temperature: Body Fluid or Urine: Refrigerated.
- CSF: Room temperature.

Stability (collection to initiation of testing):
- Body Fluid: Ambient: Unacceptable; Refrigerated: 72 hours; Frozen: Unacceptable
- CSF: Ambient: 72 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
- Urine: Ambient: 72 hours; Refrigerated: 72 hours; Frozen: Unacceptable

Oxcarbazepine or Eslicarbazepine Metabolite (MHD)

Performed: Sun-Sat
Reported: 3 days

Interpretive Data: This test measures monohydroxyoxcarbazepine (MHD). Adverse effects may include dizziness, fatigue, nausea, headache, somnolence, ataxia and tremor.

See Compliance Statement B: www.aruplab.com/CS
### New Test

**3001309**  
1p/19q Deletion by FISH  
**1P19Q_FISH**

#### Additional Technical Information

<table>
<thead>
<tr>
<th>Methodology:</th>
<th>Fluorescence in situ Hybridization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performed:</td>
<td>Monday-Friday</td>
</tr>
<tr>
<td>Reported:</td>
<td>3-7 days</td>
</tr>
</tbody>
</table>

**Specimen Required:**
- **Collect:** Tumor tissue.
- **Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect paraffin block from excessive heat. Transport block or 6 unstained (4 micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended but not necessary). (Min 3 slides)
- **Storage/Transport Temperature:** Room temperature or refrigerated. Ship in cooled container during summer months.
- **Remarks:** Include surgical pathology report. Unacceptable Conditions: Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens.
- **Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** By report

**Interpretive Data:**
- Refer to report.
- See Compliance Statement A: [www.arulab.com/CS](http://www.arulab.com/CS)

**CPT Code(s):** 88377 x2

**New York DOH Approved.**

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

### 2007949

**Paliperidone, Serum or Plasma**  
**PALIPERID**

<table>
<thead>
<tr>
<th>Performed:</th>
<th>Wed, Sat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported:</td>
<td>1-5 days</td>
</tr>
</tbody>
</table>

**Specimen Required:**
- **Patient Prep:** Pre-dose (trough) draw - At steady state concentration.
- **Collect:** Lavender (EDTA), Pink (K2EDTA), or Plain Red.
- **Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- **Storage/Transport Temperature:** Refrigerated.
- **Unacceptable Conditions:** Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
- **Stability (collection to initiation of testing):** Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 months

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.

Remove component 2011545, Paliperidone Dose
Remove component 2011546, Paliperidone Dose Frequency
Remove component 2011547, Paliperidone Route
Remove component 2011548, Paliperidone Type of Draw

### 2013284

**PD-L1 22C3 IHC with Tumor Proportion Score (TPS) Interpretation, pembrolizumab (KEYTRUDA)**  
**22C3 IP**

**HOTLINE NOTE:** Name change only.
2011549  Pentobarbital, Serum or Plasma

**Performed:** Sat  
**Reported:** 1-8 days

**Specimen Required:** Collect: Serum Pre-dose (Trough) Draw - At a Steady State Concentration or Plasma Pre-dose (Trough) Draw - At a Steady State Concentration in Plain Red, Lavender (K2EDTA), Lavender (K3EDTA), or Pink (K2EDTA).  
Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
Storage/Transport Temperature: Refrigerated.  
Unacceptable Conditions: Whole blood. Gel Separator Tubes, Light Blue (Sodium Citrate), or Yellow (SPS or ACD Solution).  
Stability (collection to initiation of testing): Ambient: 3 months; Refrigerated: 3 months; Frozen: 1 year

**Interpretive Data:** The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Toxic concentrations may cause respiratory depression, hypotension, coma, and death.

See Compliance Statement B: www.aruplab.com/CS

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.  
Remove component 2011550, Pentobarbital Dose  
Remove component 2011552, Pentobarbital Route  
Remove component 2011551, Pentobarbital Dose Frequency  
Remove component 2011553, Pentobarbital Type of Draw
### New Test

**3001170**  
**Platelet Antigen 1 Genotyping (HPA-1)**  
**HPA_1 GENO**

**Click for Pricing**

---

### Additional Technical Information

**Methodology:** Polymerase Chain Reaction/Fluorescence Monitoring  
**Performed:** Mon, Thu  
**Reported:** 2-7 days

**Specimen Required:**  
- **Collect:** Fetal Specimen: Amniotic fluid OR cultured amniocytes. If the client is unable to culture amniocytes, this can be arranged by contacting ARUP Client Services at (800) 522-2787.
- **WITH Maternal Cell Contamination Specimen** (see Note): Lavender (EDTA), Pink (K$_2$EDTA), or Yellow (ACD Solution A or B).
- **Parental Specimen:** Lavender (EDTA).
- **Specimen Preparation:** Amniotic Fluid: Transport 10 mL unspun fluid. (Min: 5 mL)
- **Cultured Amniocytes:** Transport two T-25 flasks at 80 percent confluency filled with culture media. Backup cultures must be retained at the client's institution until testing is complete.
- **Maternal Cell Contamination Specimen:** Transport 3 mL whole blood. (Min: 1 mL)
- **Whole Blood (Parental Genotyping):** Transport 3 mL whole blood. (Min: 1 mL)
- **Storage/Transport Temperature:** Amniotic Fluid: Room temperature.  
  Cultured Amniocytes: CRITICAL ROOM TEMPERATURE. Must be received within 48 hours of shipment due to liability of cells.  
  Whole Blood or Maternal Cell Contamination Specimen: Refrigerated.

**Stability (collection to initiation of testing):**  
- **Fetal Specimen:** Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable  
- **Whole Blood or Maternal Cell Contamination Specimen:** Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

**Reference Interval:** By report

**Interpretive Data:**

**Background Information for Platelet Antigen 1 Genotyping (HPA-1):**  
**Characteristics:** Spontaneous fetal intracranial bleeding may occur in 20 percent of pregnancies affected with severe perinatal alloimmune thrombocytopenia (PAT); there is a risk of fetal death. Post-transfusion purpura may occur in transfusion recipients with antibodies to a specific platelet antigen.

**Incidence:** PAT occurs in 1 in 5000 births.

**Inheritance:** For women homozygous for a rare "b" HPA allele with antibodies to the common "a" allele, there is a 50 percent risk a pregnancy will be affected if her partner is heterozygous for the "a" allele and 100 percent risk if her partner is homozygous for the "a" allele.

**Cause:** Maternal-fetal HPA incompatibility.

**Polymorphism Tested:** HPA-1 (ITGB3, GPIIIa) c.176T>C, p.L59P

**Clinical Sensitivity:** 80 percent in Caucasians, unknown in other ethnicities.

**Methodology:** PCR followed by fluorescent monitoring.

**Analytic Sensitivity and Specificity:** 99 percent.

**Limitations:** Bloody amniotic fluid specimens may give false-negative results because of maternal cell contamination. Diagnostic errors can occur due to rare sequence variations.

**Informed consent:** Recommended; forms are available at http://www.aruplab.com.

---

See Compliance Statement C: www.aruplab.com/CS

**Note:** Maternal specimen is recommended for proper test interpretation if contamination of the fetal specimen from the mother is suspected. Order Maternal Cell Contamination.

**CPT Code(s):** 81105

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
New Test
Click for Pricing

Additional Technical Information

Methodology: Polymerase Chain Reaction/Fluorescence Monitoring
Performed: Varies
Reported: 2-7 days

Specimen Required:
- **Collect: Fetal Genotyping:** Amniotic fluid OR cultured amniocytes. If the client is unable to culture amniocytes, this can be arranged by contacting ARUP Client Services at (800) 522-2787.

  - WITH Maternal Cell Contamination Specimen (see Note): Lavender (EDTA), Pink (K$_2$EDTA), or Yellow (ACD Solution A or B).

- **Parental Genotyping:** Lavender (EDTA).

  - Specimen Preparation: Amniotic Fluid: Transport 10 mL unspun fluid. (Min: 5 mL)

- **Cultured Amnioncytes:** Transport two T-25 flasks at 80 percent confluency filled with culture media. Backup cultures must be retained at the client's institution until testing is complete.

- **Maternal Cell Contamination Specimen:** Transport 3 mL whole blood. (Min: 1 mL)

  - Storage/Transport Temperature: Amniotic Fluid: Room temperature.

- **Cultured Amnioncytes:** CRITICAL ROOM TEMPERATURE. Must be received within 48 hours of shipment due to liability of cells.

- **Whole Blood or Maternal Cell Contamination Specimen:** Refrigerated.

  - Stability (collection to initiation of testing):
    - Fetal Specimen: Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
    - Whole Blood or Maternal Cell Contamination Specimen: Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Interpretive Data:

**Background Information for Platelet Antigen Genotyping Panel:**

**Characteristics:** Spontaneous fetal intracranial bleeding may occur in 20 percent of pregnancies affected with severe perinatal alloimmune thrombocytopenia (PAT); there is a risk of fetal death. Post-transfusion purpura may occur in transfusion recipients with antibodies to a specific platelet antigen.

**Incidence:** PAT occurs in 1 in 5000 births.

**Inheritance:** For women homozygous for the less common "b" HPA allele with antibodies to the common "a" allele, there is a 50 percent risk a pregnancy will be affected if her partner is heterozygous for the "a" allele and 100 percent risk if her partner is homozygous for the "a" allele.

**Cause:** Maternal-fetal HPA incompatibility.


**Clinical Sensitivity:** Variable, dependent on ethnicity.

**Methodology:** PCR followed by fluorescent monitoring.

**Analytic Sensitivity and Specificity:** 99 percent.

**Limitations:** Bloody amniotic fluid specimens may give false-negative results because of maternal cell contamination. Diagnostic errors can occur due to rare sequence variations.

**Informed consent:** Recommended; forms are available at www.aruplab.com.

See Compliance Statement C: www.aruplab.com/CS

<table>
<thead>
<tr>
<th>HPA 1-6, 15 Polymorphism</th>
<th>&quot;a&quot; Allele Common</th>
<th>&quot;b&quot; Allele Variant</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPA 1</td>
<td>T</td>
<td>C</td>
</tr>
<tr>
<td>HPA 2</td>
<td>C</td>
<td>T</td>
</tr>
<tr>
<td>HPA 3</td>
<td>T</td>
<td>G</td>
</tr>
<tr>
<td>HPA 4</td>
<td>G</td>
<td>A</td>
</tr>
<tr>
<td>HPA 5</td>
<td>G</td>
<td>A</td>
</tr>
<tr>
<td>HPA 6</td>
<td>G</td>
<td>A</td>
</tr>
<tr>
<td>HPA 15</td>
<td>C</td>
<td>A</td>
</tr>
</tbody>
</table>

**Note:** Maternal specimen is recommended for proper test interpretation if contamination of the fetal specimen from the mother is suspected. Order Maternal Cell Contamination.

**CPT Code(s):** 81105; 81106; 81107; 81108; 81109; 81110; 81112

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.
## PREGABALIN

**2011609**  
Pregabalin, Serum or Plasma

**Performed:** Wed, Sat  
**Reported:** 1-6 days

**Specimen Required:** Collect: Serum Pre-dose (Trough) Draw - At a Steady State Concentration or Plasma Pre-dose (Trough) Draw - At a Steady State Concentration in Plain Red, Lavender (K3,EDTA), Lavender (K2,EDTA), or Pink (K2,EDTA).  
**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.2 mL)  
**Storage/Transport Temperature:** Refrigerated.  
**Unacceptable Conditions:** Citrated Plasma.  
**Stability (collection to initiation of testing):** Ambient: 1 month; Refrigerated: 1 month; Frozen: 2 months

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.  
Remove component 2011894, Pregabalin Dose  
Remove component 2011895, Pregabalin Route  
Remove component 2011896, Pregabalin Dose Frequency  
Remove component 2011897, Pregabalin Type of Draw

## PREGABA U

**2012229**  
Pregabalin, Urine

**Performed:** Wed, Sat  
**Reported:** 1-6 days

## PROST INDX

**3000134**  
Prostate Health Index

**HOTLINE NOTE:** There is a numeric map change associated with this test.  
Change the numeric map for component 3000518, Total PSA from XXXXX.XXX to XXXXX.X.
New Test 3001255 14-3-3 Protein Tau, Total, CSF 14-3-3 TAU

CJD Surveillance CTR Test Request Form

Methodology: Qualitative Western Blot/Quantitative Enzyme-Linked Immunosorbent Assay/Qualitative Real-Time Quaking-Induced Conversion Performed: Varies Reported: 7-17 days

Specimen Required: Collect: CSF Specimen Preparation: The first 2 mL of CSF that flows from the tap should be discarded. Transfer 5 mL CSF to ARUP Standard Transport Tubes and freeze immediately. (Min: 2 mL) Storage/Transport Temperature: Frozen. Remarks: Completed requisition form required. Unacceptable Conditions: Specimens exposed to more than one freeze/thaw cycle. Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: Indefinitely

Reference Interval: By report

Note: Repeat testing should be collected no sooner than 2 weeks following last encounter.

CPT Code(s): 86317; 84182; 0035U

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

2003118 Quetiapine, Serum or Plasma QUETIAP

Performed: Wed Reported: 1-8 days
**New Test** | **3001312** | **RET Gene Rearrangements by FISH** | **RET_FISH**
---|---|---|---
**Methodology:** | Fluorescence in situ Hybridization | | |
**Performed:** | Varies | | |
**Reported:** | 3-7 days | | |
**Specimen Required:** | Collect: Tumor tissue. | | |
**Specimen Preparation:** | Formalin fix (10 percent neutral buffered formalin) and paraffin embed tumor tissue. Transport tissue block or 4 unstained, consecutively cut, 5-micron thick sections, mounted on positively charged glass slides. (Min: 2 slides) Protect paraffin block and/or slides from excessive heat. | | |
**Storage/Transport Temperature:** | Room temperature. Also acceptable: Refrigerated. | | |
**Remarks:** | Include surgical pathology report with reason for referral. The laboratory will not reject specimens that arrive without a pathology report but will hold the specimen until this information is received. Unacceptable Conditions: Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). No tumor in tissue. Decalcified specimens. Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable | | |
**Reference Interval:** | By report | | |
**Interpretive Data:** | Refer to report. See Compliance Statement A: www.arulab.com/CS | | |
**CPT Code(s):** | 88366 | | |
New York DOH Approved. | | | |
**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

**New Test** | **2007951** | **Risperidone and Metabolite, Serum or Plasma** | **RISPERIDON**
---|---|---|---
**Performed:** | Mon, Wed, Sat | | |
**Reported:** | 1-5 days | | |
**New Test**  
3001308  
ROS1 by FISH  
ROS1_FISH

Click for Pricing

**Additional Technical Information**

**Methodology:** Fluorescence in situ Hybridization

**Performed:** Monday-Friday

**Reported:** 3-7 days

**Specimen Required:**

- **Collect:** Tumor tissue.
- **Specimen Preparation:** Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (4-micron thick sections), positively charged slides in a tissue transport kit (ARUP supply #47808), available online through eSupply using ARUP Connector contact ARUP Client Services at (800) 522-2787 (kit recommended but not necessary). (Min: 2 slides)
- **Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
- **Remarks:** Include surgical pathology report.
- **Unacceptable Conditions:** Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5).
- **No tumor in tissue. Decalcified specimens.**

**Stability (collection to initiation of testing):**

- Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Interpretive Data:**

Refer to report.
See Compliance Statement B: www.aruplab.com/CS

**CPT Code(s):** 88366

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

2008414  
ROS1 with Interpretation by Immunohistochemistry with Reflex to FISH if Equivocal or Positive  
ROS1 IP

**HOTLINE NOTE:** There is a reflexive pattern change associated with this test.
Remove reflex to 2008418, ROS1 by FISH
Add reflex to 3001308, ROS1, FISH

0098745  
Sertraline  
SERTRALINE

**Performed:** Wed

**Reported:** 1-8 days

**Interpretive Data:** Sertraline doses ranging from 50-200 mg/d produce serum concentration ranging from 30-200 ng/mL. Dosing above 200 mg/d is associated with increased adverse effects and decreased efficacy. Adverse effects may include dry mouth, headache, dizziness, somnolence, nausea and diarrhea.

See Compliance Statement B: www.aruplab.com/CS
New Test 3001303 SS18 (SYT) (18q11) Gene Rearrangement by FISH SYT_FISH

Additional Technical Information

Test not New York DOH approved at any laboratory. An approved NPL form must accompany specimen.

Methodology: Fluorescence in situ Hybridization
Performed: Monday-Friday
Reported: 3-7 days

Specimen Required: Collect: Tumor tissue.
Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained (4 micron thick sections) positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787 (kit recommended, but not necessary). (Min 2 slides)
Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.
Remarks: Include surgical pathology report.
Unacceptable Conditions: Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5), No tumor in tissue. Decalcified specimens.
Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Reference Interval: By report

Interpretive Data:
Refer to report.
See Compliance Statement A: www.aruplab.com/CS

CPT Code(s): 88366

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.

2002270 ST2, Soluble ST2

Specimen Required: Collect: Serum Separator Tube (SST), Plain Red, Lavender (EDTA), Pink (K2EDTA), or Green (Sodium or Lithium Heparin).
Specimen Preparation: Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transport 1 mL serum or plasma in an ARUP Standard Transport Tube. (Min: 0.2 mL)
Storage/Transport Temperature: Frozen.
Unacceptable Conditions: Citrated plasma. Grossly hemolyzed or severely lipemic specimens.
Stability (collection to initiation of testing): After separation from cells: Ambient: 48 hours; Refrigerated: 10 days; Frozen: 18 months

0020044 Sulfonamides (Sulfas) SULFA

Performed: Mon
Reported: 1-8 days

Interpretive Data: This test is designed to measure sulfamethoxazole. Peak sulfonamide (total) blood levels of 5.0-15.0 mg/dL may be effective for most infections, with concentrations of 12.0-15.0 mg/dL being optimal for serious infections. Sulfonamide levels should not exceed 20.0 mg/dL. Adverse effects may include blood dyscrasias, skin rash, nausea, vomiting and fever.

2003128 Tapentadol and Metabolite, Urine, Quantitative TAPENTA UR

Performed: Sun, Wed, Fri
Reported: 1-6 days
Thallium, Whole Blood

Performed: Sun-Sat
Reported: 1-3 days

Specimen Required:
- Patient Prep: Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician).
- Collect: Royal Blue (K$_2$EDTA or Na$_2$EDTA).
- Specimen Preparation: Transport 7 mL whole blood in the original collection tube. (Min: 0.5 mL)
- Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated.
- Unacceptable Conditions: Specimens collected in tubes other than Royal Blue (EDTA). Specimens transported in containers other than a Royal Blue (EDTA) tube or Trace Element-Free Transport Tube. Heparin anticoagulant. Clotted specimens.

Reference Interval: Effective February 19, 2019
Less than or equal to 2.0 µg/L

Interpretive Data: Elevated results may be due to skin or collection-related contamination, including the use of a noncertified metal-free collection/transport tube. If contamination concerns exist due to elevated levels of blood thallium, confirmation with a second specimen collected in a certified metal-free tube is recommended.

Blood thallium levels reflect recent exposure as thallium has a biological half-life of approximately 2 to 4 days. Blood levels greater than 100 µg/L are considered toxic and greater than 300 µg/L indicate severe ingestion. After severe thallium poisonings, reported symptoms have varying times of onset and include gastroenteritis, multi-organ failure and neurologic injury. Peripheral neuropathy and alopecia are well-documented effects of acute and chronic exposure. Human health effects from low-level thallium exposure are unknown.

See Compliance Statement B: www.aruplab.com/CS

HOTLINE NOTE: Remove information found in the Note field.

Thiocyanate, 24-Hour Urine

Performed: Sun, Thu
Reported: 1-5 days

Thiocyanate, Random Urine

Performed: Sun, Thu
Reported: 1-5 days

Thiocyanate, Serum or Plasma

Performed: Sun, Thu
Reported: 1-5 days

Specimen Required:
- Collect: Plain Red, Lavender (K$_2$EDTA), Lavender (K$_3$EDTA), or Pink (K$_2$EDTA).
- Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- Storage/Transport Temperature: Refrigerated.
- Unacceptable Conditions: Whole blood. Gel Separator Tubes, Light Blue (Sodium Citrate), or Yellow (SPS or ACD Solution).
- Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: 5 days; Frozen: 5 days

HOTLINE NOTE: Remove information found in the Specimen Require Remarks field. There is also a component change associated with this test.

Remove component 2011576, Thiocyanate Dose
Remove component 2011577, Thiocyanate Dose Frequency
Remove component 2011578, Thiocyanate Route
Remove component 2011579, Thiocyanate Type of Draw
**0056200  Thrombotic Risk, DNA Panel  THROMDNA**

**Specimen Required:** Collect: Lavender (EDTA), Pink (K<sub>2</sub>EDTA) or Yellow (ACD Solution A or B).

**Specimen Preparation:** Transport 3 mL whole blood. (Min: 2 mL)

**Storage/Transport Temperature:** Refrigerated.

**Unacceptable Conditions:** Plasma or serum; collection of specimen in sodium heparin tubes.

**Stability (collection to initiation of testing):** Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month.

**Interpretive Data:** Refer to report

---

**New Test 3001184 Tiagabine Quantitative, Serum/Plasma TIAGAB SP**

**Methodology:** Quantitative High Performance Liquid Chromatography/Tandem Mass Spectrometry

**Performed:** Varies

**Reported:** 7-10 days

**Specimen Required:**

- **Patient Prep:** Pre-dose (trough) draw.
- **Collect:** Plain Red, Lavender (EDTA), or Pink (K<sub>2</sub>EDTA).

**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)

**Storage/Transport Temperature:** Refrigerated. Also acceptable: Room temperature or frozen.

**Unacceptable Conditions:** Separator tubes.

**Stability (collection to initiation of testing):** Ambient: 1 month; Refrigerated: 1 month; Frozen: 48 months

**Reference Interval:** By report

**CPT Code(s):** 80199

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

---

**2008670 Tick-Borne Disease Panel by PCR, Blood TICKPCR**

**Specimen Required:** Collect: Lavender (EDTA) or Pink (K<sub>2</sub>EDTA).

**Specimen Preparation:** Transport 1 mL whole blood. (Min: 0.6 mL)

**Storage/Transport Temperature:** Refrigerated.

**Unacceptable Conditions:** Serum, plasma, and heparinized specimens.

**Stability (collection to initiation of testing):** Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 week

**Reference Interval:**

<table>
<thead>
<tr>
<th>Available Separately</th>
<th>Components</th>
<th>Reference Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (2008665)</td>
<td>Babesia Species by PCR</td>
<td>Refer to report</td>
</tr>
<tr>
<td>Yes (2007662)</td>
<td>Ehrlichia and Anaplasma Species by PCR</td>
<td>Refer to report</td>
</tr>
</tbody>
</table>
Tricyclic Antidepressants, Quantitative, Urine

**2007515**

**Performed:** Tue, Thu, Sat

**Reported:** 1-5 days

**Interpretive Data:** Interpretive comments: Urine concentrations of tricyclic antidepressants do not correlate with signs or symptoms of therapy or toxicity. Therapeutic ranges are not established.

100 ng/mL limit of quantification: Amitriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Nordoxepin, Protriptyline

200 ng/mL limit of quantification: Clomipramine, Norclomipramine

See Compliance Statement B: www.aruplab.com/CS

---

Uroplakin II by Immunohistochemistry

**3001149**

**New Test Available Now Click for Pricing**

**Methodology:** Immunohistochemistry

**Performed:** Mon-Fri

**Reported:** 1-3 days

**Specimen Required:** Collect: Tissue. Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit (recommended but not required), (ARUP supply #47808) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787. (Min: 2 slides) If sending precut slides, do not oven bake.

Storage/Transport Temperature: Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months.

Unacceptable Conditions: Specimens submitted with non-representative tissue type. Depleted specimens.

Stability (collection to initiation of testing): Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Interpretive Data:** See Compliance Statement B: www.aruplab.com/CS

Note: All stains will be handled as "Stain and Return" unless a consultation is requested. To request a consultation, submit the pathology report, all associated case materials (clinical history, blocks, slides, etc.), and the Anatomic Pathology requisition form (#32960) in place of the Immunohistochemistry Stain Form.

**CPT Code(s):** 88342

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.

---

Urticaria-Inducing Activity with Thyroid Antibodies and Stimulating Hormone

**2005415**

**Specimen Required:** Patient Prep: Patients taking calcineurin inhibitors should stop their medication 72 hours prior to draw. Patients on prednisone should be off their medication for 2 weeks prior to draw.

Collect: Plain red.

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport tube and freeze immediately (Min: 0.5 mL) AND transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) Storage/Transport Temperature: First Specimen: CRITICAL FROZEN. Separate specimens must be submitted for this multiple test panel.

Second Specimen: Refrigerated.

Unacceptable Conditions: Specimens other than serum. Contaminated, grossly hemolyzed, or lipemic specimens.

Stability (collection to initiation of testing): First Specimen: After separation from cells: Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Second Specimen: After separation from cells: Ambient: 8 hours; Refrigerated: 1 Week; Frozen: 6 months
**2007957**  Venlafaxine and Metabolite, Serum or Plasma  VENLAFAXSP

**Performed:** Wed, Sat  
**Reported:** 1-5 days

**Specimen Required:**  
**Patient Prep:** Pre-dose (trough) draw - At steady state concentration.  
**Collect:** Lavender (EDTA), Pink (K$_2$EDTA), or Plain Red.  
**Specimen Preparation:** Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
**Storage/Transport Temperature:** Refrigerated.  
**Unacceptable Conditions:** Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD Solution).  
**Stability (collection to initiation of testing):** Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 weeks

**HOTLINE NOTE:** Remove information found in the Specimen Required Remarks field. There is also a component change associated with this test.  
Remove component 2011589, Venlafaxine Dose  
Remove component 2011590, Venlafaxine Dose Frequency  
Remove component 2011591, Venlafaxine Route  
Remove component 2011592, Venlafaxine Type of Draw

---

**0020056**  Viscosity, Serum  VIS-S

**Specimen Required:**  
**Collect:** Serum separator or plain red tube.  
**Specimen Preparation:** Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
**Storage/Transport Temperature:** Refrigerated.  
**Unacceptable Conditions:** Clotted specimens.  
**Stability (collection to initiation of testing):** After separation from cells: Ambient: 24 hours; Refrigerated: 7 days; Frozen: 1 month

**Reference Interval:** Effective February 19, 2019  
1.10-1.40 cP

**Interpretive Data:** See Compliance Statement B: www.aruplab.com/CS

---

**0080111**  Vitamin B$_6$ (Pyridoxal 5-Phosphate)  VIT B6

**Methodology:** Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

**Specimen Required:**  
**Patient Prep:** Collect specimen after an overnight fast.  
**Collect:** Green (Sodium or Lithium Heparin), Lavender (EDTA), Pink (K$_2$ EDTA), Plasma Separator Tube (PST), Serum Separator Tube (SST), or Plain Red.  
**Specimen Preparation:** Protect from light during collection, storage, and shipment. Separate from cells within 1 hour of collection. Transfer 1 mL plasma or serum to an ARUP Amber Transport Tube. (Min: 0.5 mL)  
**Storage/Transport Temperature:** Frozen.  
**Unacceptable Conditions:** Whole blood. Specimens not protected from light. Icteric specimens.  
**Stability (collection to initiation of testing):** After separation from cells: Ambient: Unacceptable; Refrigerated: 1 week; Frozen: 2 months
New Test 3001387 Voltage-Gated Potassium Channel (VGKC) Antibody, CSF VGKC CSF
Click for Pricing

Additional Technical Information

Methodology: Quantitative Radioimmunoassay
Performed: Mon, Thu
Reported: 1-8 days

Specimen Required: Collect: CSF.
Specimen Preparation: Transfer 4 mL CSF to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Storage/Transport Temperature: Refrigerated.
Unacceptable Conditions: Plasma. Grossly lipemic or icteric specimens.
Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles)

Reference Interval:

<table>
<thead>
<tr>
<th></th>
<th>Negative</th>
<th>0.0-1.1 pmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td></td>
<td>1.2 pmol/L or greater</td>
</tr>
</tbody>
</table>

Interpretive Data: Voltage-Gated Potassium Channel (VGKC) antibodies are associated with neuromuscular weakness as found in neuromyotonia (also known as Issacs syndrome) and Morvan syndrome. VGKC antibodies are also associated with paraneoplastic neurological syndromes and limbic encephalitis; however, VGKC antibody-associated limbic encephalitis may be associated with antibodies to leucine-rich, glioma-inactivated 1 protein (Lgi1) or contactin-associated protein-2 (CaspR-2) instead of potassium channel antigens. The clinical significance of this test can only be determined in conjunction with the patient's clinical history and related laboratory testing.

See Compliance Statement D: www.aruplab.com/CS

CPT Code(s): 83519

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.
**Zinc Quantitative, Whole Blood**

**ZINC WB**

**2009373**

**Performed:** Sun-Sat

**Reported:** 1-3 days

**Specimen Required:**
- **Patient Prep:** Diet, medication, and nutritional supplements may introduce interfering substances. Patient should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician).
- **Collect:** Royal Blue (K$_2$EDTA or Na$_2$EDTA).
- **Specimen Preparation:** Transport 2 mL whole blood in the original collection tube. (Min: 0.5 mL)
- **Storage/Transport Temperature:** Room temperature. Also acceptable: Refrigerated.
- **Unacceptable Conditions:** Specimens collected in tubes other than Royal Blue (EDTA). Specimens transported in containers other than a Royal Blue (EDTA) tube or Trace Element-Free Transport Tube. Heparin anticoagulant. Clotted specimens.
- **Stability (collection to initiation of testing):** Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

**Reference Interval:** Effective February 19, 2019

440.0-860.0 µg/dL

**Interpretive Data:** Elevated results may be due to skin or collection-related contamination, including the use of a noncertified metal-free collection/transport tube. If contamination concerns exist due to elevated levels of blood zinc, confirmation with a second specimen collected in a certified metal-free tube is recommended.

Zinc concentration in blood has not been shown to change significantly in deficiency or with supplementation.

See Compliance Statement B: www.aruplab.com/CS

**HOTLINE NOTE:** There is a numeric map change associated with this test.
Change the numeric map for component 2009374, Zinc Quantitative, Whole Blood from XXXXX.X to XXXX.X.
The following will be discontinued from ARUP’s test menu on February 19, 2019. Replacement test options are supplied if applicable.

<table>
<thead>
<tr>
<th>Test Number</th>
<th>Test Name</th>
<th>Refer To Replacement</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002584</td>
<td>Acanthamoeba and Naegleria Culture and Stains, CSF</td>
<td>Acanthamoeba and Naegleria Culture and Stain, CSF (3000878)</td>
</tr>
<tr>
<td>0006566</td>
<td>Adenosine 40-41 Antigens by ELIA</td>
<td>Gastrointestinal Viral Panel by PCR (2013577)</td>
</tr>
<tr>
<td>2014168</td>
<td>Agranule Syndrome (LAG1) Sequencing and Microarray</td>
<td></td>
</tr>
<tr>
<td>0001022</td>
<td>ALK Gene Rearrangements by FISH, Lung</td>
<td>ALK Gene Rearrangements by FISH, Lung (3001302)</td>
</tr>
<tr>
<td>0051432</td>
<td>Allergen, Drugs, Ampicillin</td>
<td></td>
</tr>
<tr>
<td>0091280</td>
<td>Allipurinol and Metabolite, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>0091336</td>
<td>Anoxapine and Metabolite Quantitative, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>0010702</td>
<td>BCL6 (3q27) Gene Rearrangement by FISH</td>
<td>BCL6 (3q27) Gene Rearrangement by FISH (3001311)</td>
</tr>
<tr>
<td>0091294</td>
<td>Beryllium, Serum or Plasma</td>
<td>Beryllium Quantitative, Serum or Plasma (3000997)</td>
</tr>
<tr>
<td>2013902</td>
<td>Biotin Tyrosine Kinase (BTK) Protein Expression by Flow Cytometry</td>
<td></td>
</tr>
<tr>
<td>0091223</td>
<td>Clonidine, Urine</td>
<td></td>
</tr>
<tr>
<td>0062230</td>
<td>Congenital Amegakaryocytic Thrombocytopenia (CAMT) Sequencing</td>
<td></td>
</tr>
<tr>
<td>0091303</td>
<td>Cyclophosphamide Quantitative, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>003845</td>
<td>Cytokeratin 19 (CK19) by Immunohistochemistry</td>
<td></td>
</tr>
<tr>
<td>2007233</td>
<td>DDIT3 (CHOP) (12q13) Gene Rearrangement by FISH</td>
<td>DDIT3 (CHOP) (12q13) Gene Rearrangement by FISH (3001304)</td>
</tr>
<tr>
<td>006236</td>
<td>Diamond-Blackfan Anemia (RPL11) Sequencing</td>
<td></td>
</tr>
<tr>
<td>006234</td>
<td>Diamond-Blackfan Anemia (RPL5) Sequencing</td>
<td></td>
</tr>
<tr>
<td>006238</td>
<td>Diamond-Blackfan Anemia (RPS19) Sequencing</td>
<td></td>
</tr>
<tr>
<td>006244</td>
<td>Dyskeratosis Congenita, Autosomal (TERC) Sequencing</td>
<td></td>
</tr>
<tr>
<td>0086065</td>
<td>EGFR Gene Amplification by FISH</td>
<td>EGFR Gene Amplification by FISH (3001310)</td>
</tr>
<tr>
<td>2007228</td>
<td>EWSRI (22q12) Gene Rearrangement by FISH</td>
<td>EWSRI (22q12) Gene Rearrangement by FISH (3001305)</td>
</tr>
<tr>
<td>007883</td>
<td>Filaggrin (FLG) 2 Mutations</td>
<td></td>
</tr>
<tr>
<td>0091435</td>
<td>Folic Acid, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>0081495</td>
<td>FOXO1 (FKHR1) (13q14) Gene Rearrangement by FISH</td>
<td>FOXO1 (FKHR1) (13q14) Gene Rearrangement by FISH (3001297)</td>
</tr>
<tr>
<td>0011420</td>
<td>Herpesvirus 6 Antibody, IgM Screen with Reflex to Titer by IFA</td>
<td>Herpesvirus 6 Ab, IgM by IFA, Serum (3001248)</td>
</tr>
<tr>
<td>2001536</td>
<td>IGH-BCL2 Fusion, t(14;18) by FISH</td>
<td>IGH-BCL2 Fusion, t(14;18) by FISH (3001298)</td>
</tr>
<tr>
<td>2007226</td>
<td>IGH-CCND1 Fusion, t(11;14) by FISH</td>
<td>IGH-CCND1 Fusion, t(11;14) by FISH (3001306)</td>
</tr>
<tr>
<td>0011523</td>
<td>IGH-MYC Fusion, t(8;14) by FISH</td>
<td>IGH-MYC Fusion, t(8;14) by FISH (3001299)</td>
</tr>
<tr>
<td>2001685</td>
<td>LeukoStrat CDx FLT3 Mutation Detection by PCR</td>
<td>FLT3 I1D and TK2 Mutation Detection (3001161)</td>
</tr>
<tr>
<td>2000166</td>
<td>MDM2 Gene Amplification by FISH</td>
<td>MDM2 Gene Amplification by FISH (3001301)</td>
</tr>
<tr>
<td>2013042</td>
<td>MET Gene Amplification by FISH</td>
<td>MET Gene Amplification by FISH (3001313)</td>
</tr>
<tr>
<td>0091090</td>
<td>Methaqualone Quantitative, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>2003353</td>
<td>MYC (8q24) Gene Rearrangement by FISH</td>
<td>MYC (8q24) Gene Rearrangement by FISH (3001300)</td>
</tr>
<tr>
<td>2007237</td>
<td>MYCN (N-MYC) Gene Amplification by FISH</td>
<td>MYCN (N-MYC) Gene Amplification by FISH (3001307)</td>
</tr>
<tr>
<td>0099683</td>
<td>Neisseria gonorrhoea Antibodies, Total</td>
<td>Neisseria gonorrhoea Antibody by CF, Serum (3001291)</td>
</tr>
<tr>
<td>0006604</td>
<td>1p19q Deletion by FISH</td>
<td>1p19q Deletion by FISH (3001309)</td>
</tr>
<tr>
<td>0012372</td>
<td>PhenoSense Integra Enzyme</td>
<td></td>
</tr>
<tr>
<td>2003228</td>
<td>PhenoSense Integra Inhibitor</td>
<td></td>
</tr>
<tr>
<td>0051306</td>
<td>Platelet Antigen 1 Genotyping (HPA-1)</td>
<td>Platelet Antigen 1 Genotyping (HPA-1) (3001170)</td>
</tr>
<tr>
<td>0051311</td>
<td>Platelet Antigen 15 Genotyping (HPA-15)</td>
<td>Platelet Antigen Genotyping Profile (2000193)</td>
</tr>
<tr>
<td>0051310</td>
<td>Platelet Antigen 2 Genotyping (HPA-2)</td>
<td>Platelet Antigen Genotyping Profile (2000193)</td>
</tr>
<tr>
<td>0051311</td>
<td>Platelet Antigen 3 Genotyping (HPA-3)</td>
<td>Platelet Antigen Genotyping Profile (2000193)</td>
</tr>
<tr>
<td>0051490</td>
<td>Platelet Antigen 4 Genotyping (HPA-4)</td>
<td>Platelet Antigen Genotyping Profile (2000193)</td>
</tr>
<tr>
<td>0051312</td>
<td>Platelet Antigen 5 Genotyping (HPA-5)</td>
<td>Platelet Antigen Genotyping Profile (2000193)</td>
</tr>
<tr>
<td>0051313</td>
<td>Platelet Antigen 6 Genotyping (HPA-6)</td>
<td>Platelet Antigen Genotyping Profile (2000193)</td>
</tr>
<tr>
<td>0051308</td>
<td>Platelet Antigen Genotyping Panel</td>
<td>Platelet Antigen Genotyping Profile (2000193)</td>
</tr>
<tr>
<td>2007533</td>
<td>Progressive Myoclonic Epilepsy (PME) Panel, Sequence Analysis and Exon-Level Deletion/Duplication</td>
<td></td>
</tr>
<tr>
<td>0040491</td>
<td>Protein Gene Product (PPBP) 9.5 by Immunohistochemistry</td>
<td></td>
</tr>
<tr>
<td>0006095</td>
<td>14-3-3 Protein Tau/Theta, CSF</td>
<td>14-3-3 Protein Tau, Total, CSF (3001255)</td>
</tr>
<tr>
<td>2012654</td>
<td>RET Gene Rearrangements by FISH</td>
<td>RET Gene Rearrangements by FISH (3001312)</td>
</tr>
<tr>
<td>0084115</td>
<td>ROS1 by FISH</td>
<td>ROS1 by FISH (3001308)</td>
</tr>
<tr>
<td>0006067</td>
<td>Rotavirus and Adenosine 40-41 Antigens</td>
<td>Rotavirus Antigen by EIA (0065088) or Gastrointestinal Viral Panel by PCR (2013577)</td>
</tr>
<tr>
<td>0077227</td>
<td>SS18 (SYT) (18q11) Gene Rearrangement by FISH</td>
<td>SS18 (SYT) (18q11) Gene Rearrangement by FISH (3001303)</td>
</tr>
<tr>
<td>0091574</td>
<td>Styrrichine, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>0091386</td>
<td>Ternazepin and Metabolite Quantitative, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>0091541</td>
<td>Tiagabine, Serum or Plasma</td>
<td>Tiagabine Quantitative, Serum/Plasma (3001184)</td>
</tr>
<tr>
<td>0091555</td>
<td>Tin, Total, Whole Blood</td>
<td></td>
</tr>
<tr>
<td>0091399</td>
<td>Tribexphendyl Quantitative, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>0091396</td>
<td>Trimethoprim, Serum or Plasma</td>
<td></td>
</tr>
<tr>
<td>004742</td>
<td>Tropifil DNA Co-Receptor Tropism Assay</td>
<td></td>
</tr>
<tr>
<td>003955A</td>
<td>Viscosity, Whole Blood</td>
<td>Viscosity, Serum (0020056)</td>
</tr>
</tbody>
</table>